# EDGAR Filing Document

**Accession Number:** 0000012208
**File Stem:** 0001308179-23-000427
**Filing Date:** 2023-3
**Character Count:** 248156
**Document Hash:** da84d5b7c2b0c903c87ef30960627156
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001308179-23-000427.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0001308179-23-000427

**CONFORMED SUBMISSION TYPE**: DEF 14A

**PUBLIC DOCUMENT COUNT**: 31

**FILED AS OF DATE**: 20230329

**DATE AS OF CHANGE**: 20230329

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-RAD LABORATORIES, INC.
- **CENTRAL INDEX KEY:** 0000012208
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **IRS NUMBER:** 941381833
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEF 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-07928
- **FILM NUMBER:** 23775637

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 ALFRED NOBEL DRIVE
- **CITY:** HERCULES
- **STATE:** CA
- **ZIP:** 94547
- **BUSINESS PHONE:** 5107247000

**MAIL ADDRESS:**
- **STREET 1:** 1000 ALFRED NOBEL DRIVE
- **CITY:** HERCULES
- **STATE:** CA
- **ZIP:** 94547

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIO RAD LABORATORIES INC
- **DATE OF NAME CHANGE:** 19920703

?xml version="1.0" encoding="utf-8"?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**SCHEDULE 14A**

**PROXY STATEMENT PURSUANT TO SECTION 14(a)** 

 **OF THE SECURITIES EXCHANGE ACT OF 1934** 

**(Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;)**

---

| | | | |
|:---|:---|:---|:---|
| ![](check01.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;Filed by the Registrant | ![](uncheck.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;Filed by a Party other than the Registrant |

---

---

| | |
|:---|:---|
| **Check the appropriate box:** | **Check the appropriate box:** |
| ![](uncheck.jpg) | Preliminary Proxy Statement |
| ![](uncheck.jpg) | **Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))** |
| ![](check01.jpg) | Definitive Proxy Statement |
| ![](uncheck.jpg) | Definitive Additional Materials |
| ![](uncheck.jpg) | Soliciting Material under §240.14a-12 |

---

**Bio-Rad Laboratories, Inc.**

![](im99339281x612976662.jpg)

*(Name of Registrant as Specified in Its Charter)*

*(Name of Person(s) Filing Proxy Statement, if other than the Registrant)*

---

| | |
|:---|:---|
| **Payment of Filing Fee (Check all boxes that apply):** | **Payment of Filing Fee (Check all boxes that apply):** |
| ![](check01.jpg) | **No fee required.** |
| ![](uncheck.jpg) | **Fee paid previously with preliminary materials.** |
| ![](uncheck.jpg) | **Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.** |

---

------

![](im99339281x612976662.jpg)

**Bio-Rad Laboratories, Inc.**

1000 Alfred Nobel Drive

Hercules, California 94547

# **Notice of Annual Meeting of Stockholders**![](im2638116759n1252336025.jpg)

**Tuesday, April 25, 2023**

**4:00 p.m. Pacific Daylight Time**

***1000 Alfred Nobel Drive, Hercules, California 94547***

![](lbiox1x1.jpg)

**TO THE STOCKHOLDERS OF BIO-RAD LABORATORIES, INC.:**

The annual meeting of the stockholders of Bio-Rad Laboratories, Inc. will be held at our corporate offices, 1000 Alfred Nobel Drive, Hercules, California 94547 on Tuesday, April 25, 2023 at 4:00 p.m., Pacific Daylight Time to consider and vote on:

&nbsp;&nbsp;&nbsp;&nbsp;1. The election of two directors by the holders of outstanding Class A Common Stock and four directors by the holders of outstanding Class B Common Stock;

&nbsp;&nbsp;&nbsp;&nbsp;2. A proposal to ratify the selection of KPMG LLP as our independent auditors for the fiscal year ending December 31, 2023;

&nbsp;&nbsp;&nbsp;&nbsp;3. An advisory (non-binding) vote to approve executive compensation;

&nbsp;&nbsp;&nbsp;&nbsp;4. An advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation every 1, 2 or 3 years;

&nbsp;&nbsp;&nbsp;&nbsp;5. A stockholder proposal, if properly presented at the annual meeting; and

&nbsp;&nbsp;&nbsp;&nbsp;6. Such other matters as may properly come before the meeting and at any adjournments or postponements thereof.

Our Board of Directors has fixed the close of business on February 24, 2023 as the record date for the determination of stockholders entitled to notice of and to vote at this annual meeting and at any adjournments or postponements thereof. Our stock transfer books will not be closed.

All stockholders are invited to attend the annual meeting in person, but those who are unable to do so are urged to execute and return promptly the enclosed proxy card(s) in the provided postage-paid envelope. Since the holders of a majority of the outstanding shares of each class of our common stock must be present or represented at the annual meeting to elect directors and the holders of a majority of our Voting Power must be present or represented at the annual meeting to conduct the other business matters referred to above, your promptness in returning the enclosed proxy card(s) will be greatly appreciated. Your proxy is revocable and will not affect your right to vote in person at the annual meeting in the event you attend the meeting and revoke your proxy.

This proxy statement and the accompanying proxy card(s) are first being distributed to stockholders of record on or about March 29, 2023.

Hercules, California

**March 29, 2023**

---

| |
|:---|
| By order of the Board of Directors<br> BIO-RAD LABORATORIES, INC. |
| ![](im709995665x1999167613.jpg) |
| **Timothy S. Ernst** |
| Secretary |

---

**Important Notice Regarding the Internet Availability of Proxy Materials for our 2023 Annual Meeting of Stockholders to be held on April 25, 2023: The proxy statement and annual report of Bio-Rad Laboratories, Inc. are available at www.bio-radproxy.com.**

------

**Table of Contents**

**PROXY SUMMARY**<sub>4</sub>

**PROXY STATEMENT**<sub>6</sub>

2023 ANNUAL MEETING 6

**GENERAL INFORMATION ABOUT THE MEETING AND VOTING**<sub>6</sub>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**ITEM 1.** **ELECTION OF DIRECTORS**<sub>9</sub>

DIRECTOR NOMINEES 9

**DIRECTOR COMPENSATION**<sub>12</sub>

**INFORMATION ABOUT THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE**<sub>13</sub>

CONTROLLED COMPANY 13

INDEPENDENT DIRECTORS 13

COMMITTEES OF THE BOARD OF DIRECTORS 13

DIRECTOR QUALIFICATIONS 15

DIVERSITY 15

BOARD LEADERSHIP AND RISK OVERSIGHT 16

BOARD AND STOCKHOLDER MEETING ATTENDANCE 17

TRANSACTIONS WITH RELATED PERSONS 17

COMMUNICATIONS WITH THE BOARD OF DIRECTORS 17

CORPORATE GOVERNANCE DOCUMENTS 17

---

| | |
|:---|:---|
| **ITEM 2. RATIFICATION OF SELECTION OF INDEPENDENT AUDITORS** | **18** |

---

---

| | |
|:---|:---|
| **REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS** | **18** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**ITEM 3.** **ADVISORY (NON-BINDING) VOTE TO APPROVE EXECUTIVE COMPENSATION**<br>| **20** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**ITEM 4.** **ADVISORY (NON-BINDING) VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE EXECUTIVE COMPENSATION EVERY 1, 2 OR 3 YEARS**<br>| **21** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**ITEM 5.** **STOCKHOLDER PROPOSAL: POLITICAL DISCLOSURE**<br>| **22** |

---

---

| | |
|:---|:---|
| **EXECUTIVE OFFICERS** | **24** |

---

---

| | |
|:---|:---|
| **PRINCIPAL AND MANAGEMENT STOCKHOLDERS** | **26** |

---

---

| | |
|:---|:---|
| **COMPENSATION COMMITTEE REPORT** | **27** |

---

---

| | |
|:---|:---|
| **COMPENSATION DISCUSSION AND ANALYSIS** | **28** |

---

COMPENSATION PROGRAM OBJECTIVES AND PHILOSOPHY 28

---

| | |
|:---|:---|
| STOCKHOLDER SAY-ON-PAY VOTE  | 28  |

---

------

THE COMPONENTS OF OUR EXECUTIVE COMPENSATION PROGRAM 29

OUR PROCESS FOR SETTING EXECUTIVE COMPENSATION 29

---

| | |
|:---|:---|
| **COMPENSATION TABLES** | **34** |

---

SUMMARY COMPENSATION TABLE 34

GRANTS OF PLAN-BASED AWARDS TABLE 35

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END 36

OPTION EXERCISES AND STOCK VESTED TABLE 37

PENSION BENEFITS 37

NONQUALIFIED DEFERRED COMPENSATION PLANS 37

POTENTIAL PAYMENTS ON TERMINATION OR CHANGE IN CONTROL 37

PAY RATIO DISCLOSURE 39

PAY VERSUS PERFORMANCE TABLE 39

NARRATIVE DISCLOSURE TO PAY VERSUS PERFORMANCE TABLE 41

---

| | |
|:---|:---|
| **STOCKHOLDER PROPOSALS**  | **42** |

---

---

| | |
|:---|:---|
| **OTHER MATTERS**  | **42** |

---

---

| | |
|:---|:---|
| **ANNUAL REPORT**  | **42** |

---

------

[Back to Contents](#_TOC)

## **Proxy Summary** 
This summary highlights information contained elsewhere in this proxy statement. This summary does not contain all of the information that you should consider, and you should read the entire proxy statement carefully before voting. Page references are supplied to help you find further information in this proxy statement.

#### **Bio-Rad 2023 Annual Meeting of Stockholders** 
• Date and Time: Tuesday, April 25, 2023 at 4 p.m. Pacific Daylight Time

• Location: 1000 Alfred Nobel Drive, Hercules, California 94547

• Record Date: February 24, 2023

#### **Eligibility to Vote (page 6)** 
You can vote if you are a holder of our Class A Common Stock or Class B Common Stock at the close of business on February 24, 2023.

#### **How to Cast Your Vote (page 7)** 
You can vote by any of the following methods:

• Promptly completing, signing and returning your proxy card(s) by mail;

• On the internet or by telephone, pursuant to the instructions provided on the proxy card(s) provided to you with your printed proxy materials; or

• In person, at the annual meeting.

If a bank, broker or other nominee is the record holder of your stock on February 24, 2023, you will be able to vote by following the instructions on the voting instruction form or notice that you receive from your bank, broker or other nominee.

#### **Voting Matters (pages 9, 18, 20, 21 and 22)** 

---

| | | |
|:---|:---|:---|
| **Item** | **Board Vote**<br>**Recommendation** | **Page Reference**<br>**(for more detail)** |
| &nbsp;&nbsp;&nbsp;&nbsp;1. Election of Directors <br>| FOR each Director Nominee | 9 |
| &nbsp;&nbsp;&nbsp;&nbsp;2. Ratification of Auditors<br>| FOR | 18 |
| &nbsp;&nbsp;&nbsp;&nbsp;3. Advisory Vote to Approve Executive Compensation<br>| FOR | 20 |
| &nbsp;&nbsp;&nbsp;&nbsp;4. Advisory Vote on the Frequency of Future Advisory Votes to Approve Executive Compensation Every 1, 2 or 3 Years<br>| EVERY 3 YEARS | 21 |
| &nbsp;&nbsp;&nbsp;&nbsp;5. Stockholder Proposal<br>| AGAINST | 22 |

---

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;4

------

[Back to Contents](#_TOC)

#### **Board Nominees (page 9)** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Age** | **Director**<br> **since** | **Occupation** | **Independent** | **Committee**<br>**Memberships** | **Other Public Company** <br> **Boards** |
| Jeffrey L. Edwards | 62 | 2017 | Former EVP, Chief Financial Officer of Allergan, Inc. | Yes | &nbsp;&nbsp;– Audit<br>– Compensation<br>– Legal & Regulatory Compliance<br>| FibroGen, Inc.<br> Clearside Biomedical, Inc.<br> Lifecore Biomedical, Inc. |
| Gregory K. Hinckley | 76 | 2017 | Former President of Mentor Graphics Corporation | Yes | &nbsp;&nbsp;– Audit<br>– Compensation<br>| SI-BONE, Inc. |
| Melinda Litherland | 65 | 2017 | Retired Partner, Deloitte & Touche LLP | Yes | &nbsp;&nbsp;– Audit<br>– Legal & Regulatory Compliance<br>| Rapid Micro Biosystems, Inc. |
| Arnold A. Pinkston | 64 | 2017 | Corporate Vice President, General Counsel of Edwards Lifesciences Corporation | Yes | &nbsp;&nbsp;– Legal & Regulatory Compliance<br>|  |
| Allison Schwartz | 42 | 2022 | Commercial Director of Bio-Rad Laboratories, (Canada) Limited | No |  |  |
| Norman Schwartz | 73 | 1995 | President, Chief Executive Officer and Chairman of the Board of Bio-Rad | No |  |  |

---

#### **Auditors (page 18)** 
We are asking our stockholders to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. Set forth below is summary information with respect to the aggregate fees billed for professional services rendered for the fiscal years ended December 31, 2022 and 2021 by KPMG LLP.

---

| | | |
|:---|:---|:---|
|  | **2022** | **2021** |
| Audit Fees | $7351000 | $8281000 |
| Audit-Related Fees | 0 | 0 |
| Tax Fees | 0 | 0 |
| All Other Fees | 13000 | 18000 |

---

#### **Advisory (Non-Binding) Vote to Approve Executive Compensation (page 20)** 
We are asking our stockholders to cast a non-binding advisory vote to approve the compensation of our named executive officers.

#### **Advisory (Non-Binding) Vote on the Frequency of Future Advisory Votes to Approve Executive Compensation Every 1, 2 or 3 Years (page 21)** 
We are asking our stockholders to cast a non-binding advisory vote to conduct future advisory votes to approve executive compensation EVERY THREE YEARS.

#### **Stockholder Proposal: Political Disclosure (page 22)** 
A stockholder proposal is expected to be presented for a vote at the annual meeting.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement 5

------

[Back to Contents](#_TOC)

## **Proxy Statement** 

### 2023 ANNUAL MEETING
Our Board of Directors is soliciting the enclosed proxy in connection with our 2023 annual meeting of stockholders (the "Annual Meeting") to be held our corporate offices, 1000 Alfred Nobel Drive, Hercules, California 94547 on Tuesday, April 25, 2023 at 4:00 p.m., Pacific Daylight Time, and at any adjournments or postponements thereof. Copies of this proxy statement and the accompanying notice and proxy card(s) are first being mailed on or about March 29, 2023 to all stockholders entitled to vote.

We refer to Bio-Rad Laboratories, Inc. in this proxy statement as "we," "our," the "Company" or "Bio-Rad".

## **General Information About the Meeting and Voting** 

#### **What items of business will be voted on at the Annual Meeting?** 
The items of business scheduled to be voted on at the Annual Meeting are:

• The election of two directors by the holders of outstanding Class A Common Stock and four directors by the holders of outstanding Class B Common Stock;

• A proposal to ratify the selection of KPMG LLP as our independent auditors for the fiscal year ending December 31, 2023;

• An advisory (non-binding) vote to approve executive compensation;

• An advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation every 1, 2 or 3 years;

• A stockholder proposal, if properly presented at the annual meeting; and

• Such other matters as may properly come before the meeting and at any adjournments or postponements thereof.

#### **What is included in the proxy materials?** 
The proxy materials include:

• Our proxy statement for the Annual Meeting;

• Our 2022 Annual Report to Stockholders, which consists of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022; and

• Proxy card(s) for the Annual Meeting.

#### **What shares can I vote?** 
Our securities entitled to vote at the meeting consist of Class A Common Stock and Class B Common Stock (collectively, "Common Stock"). As of the close of business on February 24, 2023 (the "Record Date"), we had 24,521,581 shares of Class A Common Stock and 5,074,130 shares of Class B Common Stock issued and outstanding.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;6

------

[Back to Contents](#_TOC)

#### **How many votes am I entitled to per share?** 
For all matters where the holders of Class A Common Stock and Class B Common Stock vote together as a class, each share of Class A Common Stock is entitled to one-tenth of a vote and each share of Class B Common Stock is entitled to one vote. For all matters where the holders of Class A Common Stock and Class B Common Stock vote separately, including the election of directors, each share of Class A Common Stock and each share of Class B Common Stock is entitled to one vote. The sum of one-tenth the number of outstanding shares of Class A Common Stock and the number of outstanding shares of Class B Common Stock constitutes our "Voting Power."

#### **What constitutes a quorum for the Annual Meeting?** 
The presence, in attendance or by proxy, of the holders of a majority of our Voting Power, as defined above, will constitute a quorum for the transaction of business; provided, however, that the election of the Class A and Class B directors shall require the presence, in attendance or by proxy, of the holders of a majority of the outstanding shares of each respective class.

#### **How many votes are needed to approve each item of business?** 
Six directors are to be elected at the meeting. The holders of Class A Common Stock, voting as a separate class, are entitled to elect two directors. The holders of Class B Common Stock, also voting as a separate class, are entitled to elect the other four directors. Our stockholders do not have any right to vote cumulatively in any election of directors. Directors elected by each class shall be elected by a majority of the votes cast in the respective class.

The proposal to ratify the appointment of our independent auditors, the advisory (non-binding) vote to approve executive compensation, the advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation every 1, 2 or 3 years, and the stockholder proposal must each receive the affirmative vote of a majority of our Voting Power present or represented by proxy at the meeting and entitled to vote on such matter in order for it to be approved.

With respect to the advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation every 1, 2 or 3 years, if none of the frequency alternatives receives the affirmative vote of a majority of our Voting Power, we will consider the frequency that receives the highest number of votes by our Voting Power to be the frequency that has been selected by our stockholders.

#### **What effect do broker non-votes and abstentions have on the items of business?** 
The term "broker non-votes" refers to shares held by a brokerage firm or other nominee (for the benefit of its client) that are represented at the meeting, but with respect to which such broker or nominee is not instructed to vote by the beneficial holder on a particular proposal and does not have discretionary authority to vote on that proposal. Brokers and nominees do not have discretionary voting authority on certain non-routine matters, including the election of directors, the advisory (non-binding) vote to approve executive compensation, the advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation every 1, 2 or 3 years, and the stockholder proposal, and accordingly, may not vote on such matters absent instructions from the beneficial holder. Broker non-votes will not be counted in determining the number of votes cast on these non-routine matters. Brokers have discretionary authority to vote on the ratification of the Company's independent auditors.

For purposes of determining the presence of a quorum, broker non-votes, as well as abstentions, will be counted as shares that are present and entitled to vote. With respect to the election of directors, broker non-votes and abstentions will not affect the outcome of a director's election. With respect to the proposal to ratify the appointment of our independent auditors, there will be no broker non-votes in connection with this proposal because brokers have discretionary authority to vote on the ratification of the Company's independent auditors, and abstentions will have the same effect as a vote against this proposal. With respect to the advisory (non-binding) vote to approve executive compensation, the advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation every 1, 2 or 3 years, and the stockholder proposal, abstentions will have the same effect as a vote against these proposals and broker non-votes will have no effect on the vote for these proposals.

#### **How do I vote?** 
If you are the record holder of your stock as of the Record Date, you may submit a proxy by executing and returning the enclosed proxy card(s) in the provided postage-paid envelope. You may also vote on the internet or by telephone, pursuant to the instructions provided on the proxy card(s) provided to you with your printed proxy materials, or you may attend the Annual Meeting and vote your shares in person.

If a bank, broker or other nominee is the record holder of your stock on the Record Date, you will be able to vote by following the instructions on the voting instruction form or notice that you receive from your bank, broker or other nominee.

#### **What happens if I do not provide instructions on how to vote or if other matters are presented for determination at the Annual Meeting?** 
Shares for which a properly executed proxy in the enclosed form is returned will be voted at the Annual Meeting in accordance with the directions on such proxy. If no voting instructions are indicated with respect to one or more of the proposals, the proxy will be voted in favor of those proposal(s), and to approve those other matters that may properly come before the Annual Meeting at the discretion of the person named in the proxy. The Board of Directors is not aware of any matters that might come before the meeting other than those mentioned in this proxy statement. If, however, any other matters properly come before the Annual Meeting, it is intended that the proxies

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement 7

------

[Back to Contents](#_TOC)

will be voted in accordance with the judgment of the person or persons voting such proxies.

#### **May I change my vote?** 
Yes. Any proxy may be revoked by the record owner of the shares at any time prior to its exercise by filing with our Secretary a written revocation or duly executed proxy bearing a later date or by attending the Annual Meeting and announcing such revocation or voting in person at the meeting. Attendance at the Annual Meeting will not, by itself, constitute revocation of a proxy. For shares held through a broker, the directions received from the broker must be followed in order to revoke a proxy, change a vote or to vote at the Annual Meeting.

#### **What rights do I have if I dissent on an item of business?** 
There are no statutory or contractual rights of appraisal or similar remedies available to those stockholders who dissent from any matter to be acted upon at the meeting.

#### **Who will bear the cost of soliciting votes for the Annual Meeting?** 
We will pay the cost of this proxy solicitation. In addition to solicitation by use of the mails, proxies may be solicited from our stockholders by our directors, officers and employees in person or by telephone, telegram or other means of communication. These directors, officers and employees will not be additionally compensated, but may be reimbursed for reasonable out-of-pocket expenses in connection with such solicitation. Arrangements will be made with brokerage houses, custodians, nominees and fiduciaries for forwarding of proxy materials to beneficial owners of shares held of record by such brokerage houses, custodians, nominees and fiduciaries and for reimbursement of their reasonable expenses incurred in connection therewith.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;8

------

[Back to Contents](#_TOC)

## **Item 1. Election of Directors** 
**The Board of Directors recommends that you vote FOR the director nominees named below for the class or classes of Common Stock that you hold.**

Our Board of Directors currently has six members. The term of each of our current directors expires as of the date of the annual meeting of stockholders or on election and qualification of his or her successor. All of our current directors are standing for re-election to our Board. The Board of Directors appointed Alice N. Schwartz effective as of April 26, 2022 a Director Emeritus. A Director Emeritus has the option to attend Board meetings and receive Board materials at the discretion of the Secretary of the Company but does not have voting power and does not receive compensation.

At the Annual Meeting, the stockholders will elect six directors. The six persons nominated are: Jeffrey L. Edwards, Gregory K. Hinckley, Melinda Litherland, Arnold A. Pinkston, Allison Schwartz, and Norman Schwartz. The table below includes biographies for each nominee and an indication of the class of Common Stock for which the person is a director nominee. Norman Schwartz is the father of Allison Schwartz. No other family relationships exist among our current and nominated directors or executive officers.

The directors elected at this meeting will serve until the next annual meeting of stockholders or until their respective successors are elected and qualified. Although it is not contemplated that any nominee will decline or be unable to serve as a director, in the event that at the meeting or any adjournments or postponements thereof any nominee declines or is unable to serve, the persons named in the enclosed proxy will, in their discretion, vote the shares subject to such proxy for another person selected by the Board.

### **DIRECTOR NOMINEES** 
**JEFFREY L. EDWARDS**

**Former EVP, Chief Financial Officer of Allergan, Inc.**

**Director Since:** 2017

**Age:** 62

**Class of Common Stock to Elect:** Class B

Mr. Edwards retired from Allergan, Inc., a multi-specialty health care company, in February 2015 after nearly 22 years at Allergan. From September 2005 to August 2014, he served as Executive Vice President, Finance and Business Development, Chief Financial Officer at Allergan. From 2003 to 2005 he served as Allergan's Corporate Vice President, Corporate Development and previously served as Senior Vice President, Treasury, Tax and Investor Relations. Prior to joining Allergan, Mr. Edwards was with Banque Paribas and Security Pacific National Bank, where he held various senior-level positions in the credit and business development functions. Mr. Edwards currently serves on the Board of Directors and as Audit Committee chair of FibroGen, Inc., a publicly traded biopharmaceutical company, on the Board of Directors, the Nominating and Corporate Governance Committee and the Audit Committee of Clearside Biomedical, Inc., a publicly traded development stage pharmaceutical company, and on the Board of Directors and as the Audit Committee Chair of Lifecore Biomedical, Inc., a publicly traded company focused on diversified health and wellness solutions. Mr. Edwards has over 30 years of public company experience. We believe that Mr. Edwards' deep financial, capital allocation, and business development experience give him the qualifications and skills to serve as a director.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement 9

------

[Back to Contents](#_TOC)

**GREGORY K. HINCKLEY**

**Former President of Mentor Graphics Corporation**

**Director Since:** 2017

**Age:** 76

**Class of Common Stock to Elect:** Class B

Mr. Hinckley retired from Mentor Graphics Corporation, a leader in computer automated software for electronics design, in July 2017 after 20 years at Mentor Graphics. From 1999 to July 2017, he served as President of Mentor Graphics. From 1997 to 1999, he served as Mentor Graphics' Executive Vice President, Chief Operating and Financial Officer. Prior to joining Mentor Graphics in 1997, Mr. Hinckley served as Chief Financial Officer for VLSI Technology, Inc., a publicly traded integrated semiconductor device company, from 1992-1997, for Crowley Maritime Corporation from 1989-1991 and for Bio-Rad from 1983-1989. He currently serves as a director and on the Audit Committee of SI-BONE, Inc., a publicly traded orthopedic device company. Mr. Hinckley also serves as a trustee and as Chair of the Board of Portland State University. Mr. Hinckley previously served as a director for several other publicly traded companies including Intermec, Inc., a publicly traded provider of automated identification and data collection (AIDC) solutions, Super Micro, a publicly traded provider of advanced computer server systems and subsystems, and Amkor Technology, a leading supplier of outsourced semiconductor interconnect services. Mr. Hinckley has over 40 years of public company experience. We believe that Mr. Hinckley's financial, operational and public board expertise give him the qualifications and skills to serve as a director.

**MELINDA LITHERLAND**

**Retired Partner, Deloitte & Touche LLP**

**Director Since:** 2017

**Age:** 65

**Class of Common Stock to Elect:** Class A

Ms. Litherland retired in 2015 as a Partner at Deloitte & Touche LLP, where she worked since 1981. She is a certified public accountant with 34 years of experience working with life science and technology companies in both audit and consulting capacities. Ms. Litherland currently serves on the Board of Directors and as Audit Committee chair of Rapid Micro Biosystems, Inc., a publicly traded life sciences technology company. Ms. Litherland is a member of the American Institute of CPAs (AICPA) and previously served for 12 years on the Board of Directors of Ronald McDonald House Charities Bay Area, including serving on the Finance Committee. We believe that Ms. Litherland's extensive financial and life sciences background gives her the qualifications and skills to serve as a director.

**ARNOLD A. PINKSTON**

**Corporate Vice President, General Counsel of Edwards Lifesciences Corporation**

**Director Since:** 2017

**Age:** 64

**Class of Common Stock to Elect:** Class A

Mr. Pinkston is currently the Corporate Vice President, General Counsel of Edwards Lifesciences Corporation, a global leader in patient-focused medical innovations for heart disease, as well as critical care and surgical monitoring. Prior to joining Edwards in July 2019, he served as the Chief Legal Officer and Corporate Secretary of CoreLogic, Inc., a leading global property information, analytics and data-enabled solutions provider from January 2018 until June 2019. From 2011 until March 2015, he served as Executive Vice President and General Counsel for Allergan, Inc., a multi-specialty health care company. From 2005 until 2011, Mr. Pinkston served as Senior Vice President, General Counsel and Secretary for Beckman Coulter, Inc., a health care diagnostics and life sciences company. From 1994 until 2005, he held various positions at Eli Lilly and Company, a global pharmaceutical company, including Vice President and Deputy General Counsel. Additionally, Mr. Pinkston was formerly a director of Janus Capital Group, a publicly owned investment firm. Mr. Pinkston has over 25 years of experience at successful public companies. We believe that Mr. Pinkston's broad corporate governance, regulatory and M&A knowledge give him the qualifications and skills to serve as a director.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement 10

------

[Back to Contents](#_TOC)

**ALLISON SCHWARTZ**

**Commercial Director at Bio-Rad Laboratories (Canada) Limited**

**Director Since:** 2022

**Age:** 42

**Class of Common Stock to Elect:** Class B

Ms. Schwartz is currently the Commercial Director at Bio-Rad Laboratories (Canada) Limited (a subsidiary of the Company), a role to which she was appointed in January 2023. Prior to this assignment, Ms. Schwartz served as the Marketing Director at Bio-Rad Laboratories (Canada) Limited from July 2021 to January 2023, and previously as the Commercial Services Director at the Company from 2016 until 2021, with accountabilities in these roles spanning global digital marketing, eCommerce, customer experience, and pricing. Since joining Bio-Rad in 2005, she has held positions in domestic and international brand development, product marketing and logistics management. We believe that Ms. Schwartz's business experience and expertise give her the qualifications and skills necessary to effectively serve as a director of our Company.

**NORMAN SCHWARTZ**

**Chairman of the Board, President and Chief Executive Officer**

**Director Since:** 1995

**Age:** 73

**Class of Common Stock to Elect:** Class B

Mr. Schwartz has been our President and Chief Executive Officer since 2003 and our Chairman of the Board since 2012. He was our Vice President from 1989 to 2002, our Group Manager, Life Science, from 1997 to 2002 and our Group Manager, Clinical Diagnostics, from 1993 to 1997. We believe Mr. Schwartz's financial and business expertise gained through over 46 years of service with our Company, including as our President and Chief Executive Officer for over 20 years, give him the qualifications and skills to serve as a director.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;11

------

[Back to Contents](#_TOC)

## **Director Compensation** 
The compensation of our Board of Directors is established by the Chairman of the Board. Our Human Resources Department periodically provides the Chairman of the Board with market information on, and trends regarding, director compensation from other companies including our peer group (our method of determining our peer group is described in the section titled "Our Process for Setting Executive Compensation" below).

Employee directors receive no additional compensation for Board service.

Our Board of Directors approved the compensation policy that was in effect during the year ended December 31, 2022 for our non-employee directors on December 6, 2019, providing for the payment of cash fees as follows:

---

| | |
|:---|:---|
| **Board Role** | **Cash Fees** <br> **($)** |
| Board Member | 125000 |
| Lead Independent Director | 15000 |
| Audit Committee Chair | 20000 |
| Audit Committee Member | 10000 |
| Legal & Regulatory Compliance Committee Chair | 10000 |
| Legal & Regulatory Compliance Committee Member | 5000 |
| Compensation Committee Chair | 5000 |
| Compensation Committee Member | 3000 |

---

Pursuant to this policy, we pay no other types of meeting fees or committee service retainers to Board members. We also reimburse Board members for travel expenses relating to Board meetings. Our directors received no benefits in fiscal 2022 under defined pension or defined contribution plans. We did not award equity to non-employee directors during 2022, and none of our non-employee directors held any equity awards as of December 31, 2022.

In 2022, a special committee of the Board of Directors was formed for a limited purpose. The following fees were approved for service on the special committee: One-time fee for Special Committee Member: $5,000. One-time fee for Special Committee Chair: $8,000.

The following table provides information about director compensation during 2022 for our non-employee directors. Norman Schwartz serves as our Chief Executive Officer and his compensation is disclosed in the "Summary Compensation Table" beginning on page 34 of this Proxy Statement. Allison Schwartz serves as an employee and her compensation is disclosed under "Transactions with Related Persons" beginning on page 17 of this Proxy Statement.

---

| | | |
|:---|:---|:---|
| **Name** | **Fees Earned or** <br> **Paid in Cash** <br> **($)** | **Total** <br> **($)** |
| Jeffrey L. Edwards | 150000 | 150000 |
| Gregory K. Hinckley | 161000 | 161000 |
| Melinda Litherland | 155000 | 155000 |
| Arnold A. Pinkston | 140000 | 140000 |
| Alice N. Schwartz<sup>(1)</sup> | 40179 | 40179 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Alice Schwartz retired from her position as a director effective as of April 26, 2022, and the Board of Directors appointed her a Director Emeritus effective as of April 26, 2022. A Director Emeritus has the option to attend Board meetings and receive Board materials at the discretion of the Secretary of the Company but does not have voting power and does not receive compensation. The fees shown are for her service as a director until April 26, 2022. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Alice Schwartz retired from her position as a director effective as of April 26, 2022, and the Board of Directors appointed her a Director Emeritus effective as of April 26, 2022. A Director Emeritus has the option to attend Board meetings and receive Board materials at the discretion of the Secretary of the Company but does not have voting power and does not receive compensation. The fees shown are for her service as a director until April 26, 2022. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Alice Schwartz retired from her position as a director effective as of April 26, 2022, and the Board of Directors appointed her a Director Emeritus effective as of April 26, 2022. A Director Emeritus has the option to attend Board meetings and receive Board materials at the discretion of the Secretary of the Company but does not have voting power and does not receive compensation. The fees shown are for her service as a director until April 26, 2022. |

---

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement 12

------

[Back to Contents](#_TOC)

## **Information About the Board of Directors and Corporate Governance** 

### CONTROLLED COMPANY
Because the Schwartz family holds more than 50% of our Voting Power and the votes necessary to elect a majority of our Board of Directors through its ownership of our Class B Common Stock, we are a "controlled company" for purposes of the New York Stock Exchange listing standards.

### INDEPENDENT DIRECTORS
Jeffrey L. Edwards, Gregory K. Hinckley, Melinda Litherland and Arnold A Pinkston are "independent" directors, as determined in accordance with the independence standards set forth in Section 303A.02 of the New York Stock Exchange Listed Company Manual.

### COMMITTEES OF THE BOARD OF DIRECTORS
Our Board of Directors has an Audit Committee, a Compensation Committee and a Legal and Regulatory Compliance Committee. Because we are a "controlled company," as explained above, our Board of Directors has no nominating committee or other committees performing similar functions. Our Board of Directors also may from time to time appoint other special committees formed for a particular purpose. In 2022, a special committee of the Board of Directors was formed for a limited purpose, and this special committee has now been disbanded. Gregory K. Hinckley served as Chair of the special committee and Jeffrey L. Edwards, Melinda Litherland and Arnold A. Pinkston served as members of the special committee. The special committee met two times in 2022.

---

| | | | |
|:---|:---|:---|:---|
| **Current Director** | **Audit Committee** | **Compensation** <br>**Committee** | **Legal & Regulatory** <br>**Compliance Committee** |
| Jeffrey L. Edwards | ![](lbiox13x1.jpg) | ![](lbiox13x1.jpg)\* | ![](lbiox13x1.jpg) |
| Gregory K. Hinckley\*\* | ![](lbiox13x2.jpg) | ![](lbiox13x2.jpg) |  |
| Melinda Litherland | ![](lbiox13x1.jpg)\* |  | ![](lbiox13x1.jpg) |
| Arnold A. Pinkston |  |  | ![](lbiox13x2.jpg)\* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\* Chair of Committee<br>\*\* Lead Independent Director | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\* Chair of Committee<br>\*\* Lead Independent Director | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\* Chair of Committee<br>\*\* Lead Independent Director | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\* Chair of Committee<br>\*\* Lead Independent Director |

---

![](lbiox1x1.jpg)

##### **AUDIT COMMITTEE** 
During 2022, the Audit Committee was comprised of Jeffrey L. Edwards, Gregory K. Hinckley and Melinda Litherland, all of whom are "independent" directors as determined in accordance with the independence standards set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 303A.02 of the New York Stock Exchange Listed Company Manual. Each director on the Audit Committee is able to read and understand fundamental financial statements, including a company's balance sheet, income statement and cash flow statement. Our Board of Directors has determined that each of Jeffrey L. Edwards, Gregory K. Hinckley and Melinda Litherland qualifies as an audit committee financial expert.

Our Board of Directors adopted an Audit Committee Charter on June 7, 2000 and amended it most recently on February 21, 2018, a copy of which is available at the Corporate Governance section of our website, www.bio-rad.com. As set forth in the Audit Committee Charter, the purpose of our Audit Committee is to assist our Board of Directors with its oversight responsibilities regarding: (i) the integrity of our financial statements; (ii) our compliance with legal and regulatory requirements; (iii) our independent auditor's qualifications and independence; and (iv) the performance of our internal audit function and independent auditor.

Our Audit Committee is directly responsible for the appointment, compensation, retention and oversight of the work of any independent auditor we engage, including resolution of any disagreements between our management and the independent auditor regarding financial reporting, and is responsible for reviewing and evaluating our accounting policies and system of internal accounting controls. In addition, our Audit Committee reviews the scope of our independent auditor's audit of our financial statements, reviews and discusses our audited financial statements with management, approves in advance audit and non-audit services performed by our independent auditors,

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;13

------

[Back to Contents](#_TOC)

reviews significant financial risk exposures, reviews legal matters that could have a significant impact on financial statements, prepares the annual Audit Committee reports that are included in our proxy statements and annually reviews the Audit Committee's performance and the Audit Committee Charter, among other responsibilities. Our Audit Committee has the authority to obtain advice and assistance from, and receive appropriate funding from us for, any independent counsel, experts or advisors that the Audit Committee believes to be necessary or appropriate in order to enable it to carry out its duties. Our Audit Committee Charter and Corporate Governance Guidelines provide that the members of the Audit Committee may not serve on the audit committees of the boards of directors of more than two other companies at the same time as they are serving on our Audit Committee unless our Board of Directors determines that such simultaneous service would not impair the ability of such member to effectively serve on our Audit Committee. The Board of Directors has determined that Jeffrey L. Edwards' service on the audit committee of three other companies at the same time as he serves on our Audit Committee does not impair his ability to effectively serve on our Audit Committee. Our Audit Committee met nine times in 2022. A more complete discussion is provided in the "Report of the Audit Committee of the Board of Directors" of this proxy statement.

![](lbiox1x1.jpg)

##### **COMPENSATION COMMITTEE** 
During 2022, the Compensation Committee was comprised of Jeffrey L. Edwards and Gregory K. Hinckley. The Compensation Committee met five times in 2022 to make determinations regarding compensation for the senior management team. Mr. Edwards and Mr. Hinckley are "independent" directors, as stated above, and meet the definition of a "non-employee director" within the meaning of Rule 16b-3 under the Securities Exchange Act of 1934, as amended. Our Board of Directors adopted a Compensation Committee charter on July 24, 2013 and amended it most recently on October 23, 2019, a copy of which is available at the Corporate Governance section of our website, www.bio-rad.com. The Compensation Committee has overall responsibility for evaluating and approving certain elements of the compensation of our executives. A discussion of the Compensation Committee's duties and functions is provided in the "Compensation Discussion and Analysis" section of this proxy statement.

![](lbiox1x1.jpg)

##### **COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION** 
No member of our Compensation Committee was at any time during 2022 or at any other time an officer or employee of the Company, except that Gregory K. Hinckley was an officer (Vice President and Chief Financial Officer) of the Company from 1983-1989. No member of our Compensation Committee had any relationship with the Company requiring disclosure under Item 404 of Regulation S-K promulgated by the Securities and Exchange Commission.

None of our executive officers has served on the board of directors or compensation committee of any other entity that has or has had an executive officer who served as a member of our Board of Directors or Compensation Committee during 2022.

![](lbiox1x1.jpg)

##### **LEGAL AND REGULATORY COMPLIANCE COMMITTEE** 
The Legal and Regulatory Compliance Committee was formed on April 26, 2017. During 2022, the Legal and Regulatory Compliance Committee was composed of Arnold A. Pinkston, Jeffrey L. Edwards and Melinda Litherland. The Legal and Regulatory Compliance Committee met four times in 2022. Our Board of Directors adopted a Legal and Regulatory Compliance Committee charter on April 26, 2017 and amended it on February 20, 2019, a copy of which is available at the Corporate Governance section of our website, www.bio-rad.com. The Legal and Regulatory Compliance Committee has responsibility for assisting the Board with its oversight of (i) the Company's compliance with the Foreign Corrupt Practices Act of 1977 and other anti-corruption, anti-kickback and false-claims laws, (ii) the Company's Compliance Program and related compliance policies, and (iii) the Company's cybersecurity risk management programs and reviewing with management the Company's cybersecurity, data privacy and other risks relevant to the Company's information technology controls and security.

![](lbiox1x1.jpg)

##### **NOMINATING COMMITTEE FUNCTIONS** 
Our Board of Directors does not have a standing nominating committee or a committee performing similar functions. Because we are a "controlled company" as stated above, we are not required to have a standing nominating committee comprised solely of independent directors. Our Board of Directors believes that it is appropriate for us not to have a standing nominating committee because we are controlled by the Schwartz family. Notwithstanding this, each member of our Board of Directors participates in the consideration of director nominees. Gregory K. Hinckley, Jeffrey L. Edwards, Melinda Litherland and Arnold A. Pinkston are all "independent" directors, as stated above; Allison Schwartz and Norman Schwartz are not.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;14

------

[Back to Contents](#_TOC)

Our Board of Directors has not adopted a charter governing the director nomination process. However, it is the policy of our Board of Directors to consider stockholder nominations for candidates for membership on our Board of Directors that are properly submitted as set forth below under the caption "Communications with the Board of Directors" and the section titled "Stockholder Proposals." The stockholder must submit a detailed resume of the candidate together with a written explanation of the reasons why the stockholder believes that the candidate is qualified to serve on our Board of Directors. In addition, the stockholder must include the written consent of the candidate, provide any additional information about the candidate that is required to be included in a proxy statement pursuant to the rules and regulations of the Securities and Exchange Commission and the Company's Amended and Restated Bylaws, and must also describe any arrangements or undertakings between the stockholder and the candidate regarding the nomination.

### DIRECTOR QUALIFICATIONS
The director qualifications our Board of Directors has developed to date focus on what our Board of Directors believes to be those competencies that are essential for effective service on our Board of Directors. Qualifications for directors include technical, operational and/or economic knowledge of our business and industries; experience in operational, financial and/or administrative management; financial and risk management acumen; and experience in or familiarity with international business, markets and cultures, technological trends and developments, competence in environmental, social and governance (ESG) issues, including but not limited to issues relating to sustainability and climate change and diversity and inclusion, competence in risk evaluation and mitigation, and corporate securities and tax laws. While a candidate may not possess every one of these qualifications, his or her background should reflect many of these qualifications. In addition, a candidate should possess integrity and commitment according to the highest ethical standards; be consistently available and committed to attending meetings; be able to challenge and share ideas in a positive and constructively critical manner; and be responsive to our needs and fit in with other Board members from a business culture perspective.

Our Board of Directors identifies director nominees by first evaluating the current members of our Board of Directors who are willing to continue in service. Current members with qualifications and skills that are consistent with our Board of Directors' criteria for Board service are re-nominated. As to new candidates, our Board of Directors generally polls its members and members of our management for their recommendations and may consult third party advisors. Our Board of Directors may also review the composition and qualification of the boards of our competitors and may seek input from industry experts or analysts. Our Board of Directors reviews the qualifications, experience and background of the candidates, and as discussed below, considers diversity in these areas among all the Board members. In making its determinations, our Board of Directors evaluates each individual in the context of the Board as a whole, with the objective of assembling a group that can best perpetuate our success and represent stockholder interests through the exercise of sound judgment. Any recommendations properly submitted by stockholders will be processed and are subject to the same criteria as any other candidates.

Each of the nominees included in the enclosed proxy card(s) was recommended for inclusion by all of the members of our Board of Directors.

### DIVERSITY
![](im2950710486n808879408.jpg)

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;15

------

[Back to Contents](#_TOC)

Our assessment of the qualifications of nominees for the Board of Directors includes consideration of their demographic backgrounds, including, without limitation, gender, race and ethnicity. While a nominee's demographic background is an important consideration, nominees are not chosen or excluded solely or primarily on that basis; instead, we focus on skills, experience and background that can lead to an effective Board and complement or supplement existing skills and experience of the Board. We seek to nominate directors with a variety of complementary backgrounds and skills so that as a group, the Board will possess the appropriate talent, skills and expertise to oversee our businesses. As set forth above, the qualifications we look for in nominees for directors (both new candidates and current Board members) include technical and operational knowledge of our business and industries; experience in operational, financial and/or risk management; familiarity with international business, markets and cultures and technological trends and developments, competence in environmental, social and governance (ESG) issues, including but not limited to issues relating to sustainability and climate change and diversity and inclusion, competence in risk evaluation and mitigation, as well as corporate securities and tax laws. Because not every nominee will possess all of these qualifications, our Board considers diversity in these and other factors when evaluating each nominee in the context of the Board as a whole. We strive to build a diverse board representing a range of backgrounds, experiences and perspectives. Our Board is committed to building on its diversity in future refreshment opportunities.

### BOARD LEADERSHIP AND RISK OVERSIGHT
Our Board of Directors does not have a policy regarding the separation of the roles of Chief Executive Officer and Chairman of the Board as the Board believes it is in the best interest of the Company to make that determination based on the position and direction of the Company and the membership of the Board. Our Board of Directors has determined that having Norman Schwartz serve as Chief Executive Officer and Chairman of the Board is in the best interest of the Company's stockholders at this time. This structure permits Mr. Schwartz to manage our day-to-day operations and oversee the Board's activities efficiently.

Our Corporate Governance Guidelines provide that in the absence of an independent Chairman of the Board, the designation of a Lead Independent Director facilitates Board processes and controls and strengthens the cohesiveness and effectiveness of the Board as a whole. The duties of the Lead Independent Director set forth in our Corporate Governance Guidelines include the following: (i) preparing the agenda for, calling and presiding over executive sessions of the independent directors; (ii) serving as a sounding board for the Chairman and, on certain matters, acting as a liaison between the independent directors and the Chairman; (iii) in the event of the absence or the incapacity of the Chairman, presiding over Board meetings and acting as the spokesperson for the Board, and if requested by the Board, being available for consultation and direct communication with major stockholders; (iv) providing his/her unique perspective, as Lead Independent Director, to the Compensation Committee in connection with its annual formal evaluation of the CEO's performance; (v) having the capacity to suggest to the Chairman that particular items be placed on the final agenda of each Board meeting; (vi) informally consulting with other directors from time to time regarding the number and length of Board meetings, the quality, quantity, timeliness, scope and organization of pre-meeting materials and Board meeting presentations and providing appropriate suggestions regarding the same to the Chairman; (vii) receiving notice of all committee meetings and having the ability to attend and observe (in an ex-officio capacity) from time to time committee meetings where appropriate to facilitate the execution of the Lead Independent Director's duties; (viii) in appropriate circumstances, upon consultation with the Board, providing counsel to the Chairman with respect to the retention of consultants, legal counsel or other independent advisors that may assist the Board in the performance of its duties from time to time; and (ix) performing such other functions as directed by the independent directors from time to time. Gregory K. Hinckley is currently the Lead Independent Director.

Companies face a variety of risks, including credit risk, liquidity risk and operational risk. The Board of Directors believes an effective risk management process will timely identify the material risks that the Company faces, communicate necessary information with respect to material risks to senior executives and, as appropriate, to the Board of Directors or the relevant Board committee, implement appropriate and responsive risk management strategies consistent with the Company's risk profile and integrate risk management into the Company's decision-making. We have a Chief Compliance Officer that reports to the Chief Executive Officer. Our entire Board of Directors oversees general risk management of the Company and continually works, with the input of the Company's executive officers, to assess and analyze the most likely areas of future risk for the Company. The Board of Directors also encourages management to promote a corporate culture that incorporates risk management into the Company's corporate strategy and day-to-day business operations. Our Board of Directors oversees risks relating to environmental, social and governance (ESG) matters. In addition, our Audit Committee assists our Board of Directors with oversight of the Company's financial statements, significant financial risk exposures, compliance with legal and regulatory requirements, and oversight of the independent auditor. Also, the Legal and Regulatory Compliance Committee assists the Board with its oversight of (i) the Company's compliance with the Foreign Corrupt Practices Act of 1977 and other anti-corruption, anti-kickback and false-claims laws, (ii) the Company's Compliance Program and related compliance policies, and (iii) the Company's cybersecurity risk management programs and reviewing with management the Company's cybersecurity, data privacy and other risk relevant to the Company's information technology controls and security. We believe that the leadership structure of our Board of Directors supports effective oversight of the Company's risk management.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;16

------

[Back to Contents](#_TOC)

### BOARD AND STOCKHOLDER MEETING ATTENDANCE
During 2022, our Board of Directors held a total of ten meetings (including regularly scheduled and special meetings), and no director attended fewer than 75% of such meetings and meetings of any committee on which such director served. Every member of our Board of Directors that is standing for re-election is expected to attend our annual meeting of stockholders, absent extraordinary circumstances such as a personal emergency. All of our directors who were serving at the time of our annual meeting of stockholders last year attended the annual meeting.

### TRANSACTIONS WITH RELATED PERSONS
We maintain various policies and procedures relating to the review, approval, or ratification of transactions in which we are a participant and in which any of our directors, executive officers, greater than 5% stockholders or their family members have a direct or indirect material interest. Our Management Guidelines provide that our Board or certain executive officers, depending on the dollar value of the transaction, review and approve all material transactions through the expenditure approval procedures set forth in the Management Guidelines. Our Code of Business Ethics and Conduct, which applies to all of our directors, officers, employees, and in some cases, their family members, prohibits arrangements, agreements and acts which are, or may give the impression of being, conflicts of interest with us and requires prompt disclosure to the Corporate Compliance Department and the individual's manager, if applicable, of an actual or potential conflict of interest. In addition, we have a Conflict of Interest Policy for Executive Officers and Directors which provides additional conflict of interest controls for our executive officers and directors. Each quarter we also require our regional sales managers and financial officers to sign and send a written representation letter to the corporate financial reporting group wherein they are asked to disclose any related party transactions of which they are aware. In addition, each year we require our directors and executive officers to complete a questionnaire which, among other things, identifies transactions or potential transactions with us in which a director or an executive officer or one of their family members or associate entities has an interest.

During 2022 and until January 2023, our director Allison Schwartz was the Marketing Director at Bio-Rad Laboratories (Canada) Limited. For fiscal year 2022, in connection with her employment in this role, Ms. Schwartz received a grant of 167 shares of the Company's Class A restricted stock units, and base salary and bonus in the amount of $231,114. In addition, Ms. Schwartz received the following benefits relating to her expat assignment for the Company in Canada: (A) $365,410 for Canadian federal and provincial taxes applicable to Allison Schwartz's overall compensation for her expat assignment in Canada (including a US tax gross up of $49,536); and (B) $57,176 for housing, car lease, utilities, insurance, and moving company expense (including a US tax gross up of $17,721.) Beginning in January 2023, our director Allison Schwartz has been the Commercial Director at Bio-Rad Laboratories (Canada) Limited.

### COMMUNICATIONS WITH THE BOARD OF DIRECTORS
Individuals, including stockholders, may contact an individual director, the Board as a group, or a specified Board committee or group, including the non-employee directors or independent directors as a group, by writing to Attention: Corporate Secretary, Bio-Rad Laboratories, Inc., 1000 Alfred Nobel Drive, Hercules, California 94547. The Corporate Secretary will promptly forward all such communications to the Chairman of the Board. Gregory K. Hinckley is currently the Lead Independent Director and presides over the meetings of our independent directors as a group.

### CORPORATE GOVERNANCE DOCUMENTS
Our commitment to good corporate governance is embodied in our Corporate Governance Guidelines. The Corporate Governance Guidelines set forth the Board's processes and procedures to assist it in the exercise of its responsibilities and to serve the interests of the Company and its stockholders.

Our Corporate Governance Guidelines, along with our Code of Business Ethics and Conduct, Audit Committee Charter, Compensation Committee Charter, and Legal and Regulatory Compliance Committee Charter, are available at the Corporate Governance section of our website, www.bio-rad.com. Stockholders may also obtain a printed copy of these documents without charge by writing to the Corporate Secretary at the address indicated above.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;17

------

[Back to Contents](#_TOC)

## **Item 2. Ratification of Selection of Independent Auditors** 
**The Board of Directors recommends that you vote FOR ratification of KPMG LLP to serve as our independent auditors for the fiscal year ending December 31, 2023**

Our Board of Directors has selected KPMG LLP, independent registered public accountants, to serve as our auditors for the fiscal year ending December 31, 2023. A representative of KPMG LLP is expected to attend the Annual Meeting to make a statement if he or she desires to do so and to respond to appropriate questions.

Although we are not required to do so, we wish to provide our stockholders with the opportunity to express their opinion on the selection of auditors, and accordingly we are submitting a proposal to ratify the selection of KPMG LLP. If our stockholders should fail to ratify this proposal, our Board of Directors will consider the selection of another auditing firm.

## **Report of the Audit Committee of the Board of Directors** 
Our Audit Committee was established in 1992. Our Board of Directors adopted an Audit Committee charter on June 7, 2000 and amended it most recently on February 21, 2018, a copy of which is available at the Corporate Governance section of our website, www.bio-rad.com. During the fiscal year ended December 31, 2022, the Audit Committee was comprised of Jeffrey L. Edwards, Gregory K. Hinckley and Melinda Litherland, all of whom are "independent" directors, as determined in accordance with the independence standards set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 303A.02 of the New York Stock Exchange Listed Company Manual.

Our management is responsible for our internal controls and our financial reporting process. Our independent accountants are responsible for performing an independent audit of our consolidated financial statements in accordance with generally accepted accounting practices, attesting to the effectiveness of the Company's internal control over financial reporting and issuing reports thereon. Our Audit Committee's responsibility is to monitor and oversee these processes. The following is our Audit Committee's report submitted to the Board of Directors for the fiscal year ended December 31, 2022.

Our Audit Committee has:

• reviewed and discussed our audited financial statements with management;

• reviewed and discussed our assessment of internal control over financial reporting with management;

• discussed with KPMG LLP, our independent auditors, the matters required to be discussed by the applicable requirements of the Public Accounting Oversight Board and the Securities and Exchange Commission; and

• received the written disclosures and the letter from KPMG LLP, our independent auditors, required by applicable requirements of the Public Accounting Oversight Board regarding our independent auditors' communications with the Audit Committee concerning independence, and has discussed with our independent auditors the independent auditors' independence.

Based on the review and discussions referred to above, our Audit Committee recommended to our Board of Directors that the audited consolidated financial statements be included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 for filing with the Securities and Exchange Commission.

THE AUDIT COMMITTEE Melinda Litherland Jeffrey L. Edwards Gregory K. Hinckley

The Audit Committee report shall not be deemed "soliciting material" or incorporated by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act or the Exchange Act and shall not otherwise be deemed filed under these Acts.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;18

------

[Back to Contents](#_TOC)

*Audit Fees, Audit-Related Fees, Tax Fees and All Other Fees:* Set forth below are the aggregate fees billed for professional services rendered for the fiscal years ended December 31, 2022 and 2021 by KPMG LLP.

---

| | | |
|:---|:---|:---|
|  | **2022** | **2021** |
| Audit Fees<sup>(1)</sup> | $7351000 | $8281000 |
| Audit-Related Fees<sup>(2)</sup> | 0 | 0 |
| Tax Fees<sup>(3)</sup> | 0 | 0 |
| All Other Fees<sup>(4)</sup> | 13000 | 18000 |
| &nbsp;&nbsp;&nbsp;&nbsp;(1) Audit Fees included aggregate fees for professional services performed in connection with the audit of our annual consolidated financial statements and internal controls, the reviews of our consolidated financial statements included in our Quarterly Reports on Form 10-Q, issuance of comfort letters and consents related to SEC registration statements, and attestation services for the statutory audits of international subsidiaries. The fees incurred for KPMG LLP's services for fiscal year 2021 are set forth in our 2022 Proxy Statement filed with the SEC on March 30, 2022 and have been updated in this 2023 Proxy Statement to reflect final amounts of fees incurred. Such fees for fiscal year 2022 are subject to subsequent adjustment in our 2024 Proxy Statement if final amounts billed differ from the current estimates.<br>(2) Audit-Related Fees included aggregate fees for services rendered during the fiscal year for assurance and related services that are reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported under "Audit Fees."<br>(3) Tax Fees included aggregate fees for professional services performed in connection with tax planning and tax compliance.<br>(4) All Other Fees included fees for (i) performing agreed upon procedures in relation to the Company's submission to the California Department of Toxic Substance Control and Contra Costa County Health and Services Hazardous Materials Program in 2021 and 2022, and (ii) providing negative assurance associated with Switzerland gender pay gap analysis in 2021. | &nbsp;&nbsp;&nbsp;&nbsp;(1) Audit Fees included aggregate fees for professional services performed in connection with the audit of our annual consolidated financial statements and internal controls, the reviews of our consolidated financial statements included in our Quarterly Reports on Form 10-Q, issuance of comfort letters and consents related to SEC registration statements, and attestation services for the statutory audits of international subsidiaries. The fees incurred for KPMG LLP's services for fiscal year 2021 are set forth in our 2022 Proxy Statement filed with the SEC on March 30, 2022 and have been updated in this 2023 Proxy Statement to reflect final amounts of fees incurred. Such fees for fiscal year 2022 are subject to subsequent adjustment in our 2024 Proxy Statement if final amounts billed differ from the current estimates.<br>(2) Audit-Related Fees included aggregate fees for services rendered during the fiscal year for assurance and related services that are reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported under "Audit Fees."<br>(3) Tax Fees included aggregate fees for professional services performed in connection with tax planning and tax compliance.<br>(4) All Other Fees included fees for (i) performing agreed upon procedures in relation to the Company's submission to the California Department of Toxic Substance Control and Contra Costa County Health and Services Hazardous Materials Program in 2021 and 2022, and (ii) providing negative assurance associated with Switzerland gender pay gap analysis in 2021. | &nbsp;&nbsp;&nbsp;&nbsp;(1) Audit Fees included aggregate fees for professional services performed in connection with the audit of our annual consolidated financial statements and internal controls, the reviews of our consolidated financial statements included in our Quarterly Reports on Form 10-Q, issuance of comfort letters and consents related to SEC registration statements, and attestation services for the statutory audits of international subsidiaries. The fees incurred for KPMG LLP's services for fiscal year 2021 are set forth in our 2022 Proxy Statement filed with the SEC on March 30, 2022 and have been updated in this 2023 Proxy Statement to reflect final amounts of fees incurred. Such fees for fiscal year 2022 are subject to subsequent adjustment in our 2024 Proxy Statement if final amounts billed differ from the current estimates.<br>(2) Audit-Related Fees included aggregate fees for services rendered during the fiscal year for assurance and related services that are reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported under "Audit Fees."<br>(3) Tax Fees included aggregate fees for professional services performed in connection with tax planning and tax compliance.<br>(4) All Other Fees included fees for (i) performing agreed upon procedures in relation to the Company's submission to the California Department of Toxic Substance Control and Contra Costa County Health and Services Hazardous Materials Program in 2021 and 2022, and (ii) providing negative assurance associated with Switzerland gender pay gap analysis in 2021. |

---

The Audit Committee pre-approves each and every service performed by our independent auditors, including the services described in each of the four subcategories above.

Our Audit Committee has considered whether the provision of services described above under the caption "Audit Fees, Audit-Related Fees, Tax Fees and All Other Fees" is compatible with maintaining our independent auditors' independence and has determined that the provision of such service to us does not compromise the independent auditor's independence.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;19

------

[Back to Contents](#_TOC)

## **Item 3. Advisory (Non-Binding) Vote to Approve Executive Compensation** 
**The Board of Directors recommends that you vote FOR the approval of the advisory resolution to approve executive compensation.**

The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, which we refer to as the Dodd-Frank Act, provides our stockholders with an opportunity to vote on a proposal to approve, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in this proxy statement in the Compensation Discussion and Analysis section and the related executive compensation tables. Accordingly, we are asking stockholders to approve, on an advisory (non-binding) basis, the following advisory resolution (the "Advisory Resolution") at our annual meeting of stockholders:

"RESOLVED, that the compensation of the Company's named executive officers, as disclosed in the Annual Proxy Statement for the 2023 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the Compensation Tables, and the other related tables and disclosure, is hereby APPROVED."

The Board of Directors recommends a vote FOR this resolution because it believes that the policies and practices described in the Compensation Discussion and Analysis are effective in achieving the Company's goals of attracting, retaining and motivating our executives, rewarding individual and Company performance and aligning the executives' long-term interests with those of the stockholders.

We encourage stockholders to read the Compensation Discussion and Analysis beginning on page 28 of this proxy statement, as well as the Compensation Tables and related narrative, appearing on pages 34 through 42, which provide detailed information on the Company's compensation policies and practices and the compensation of our named executive officers.

This "say-on-pay" vote is a non-binding advisory vote. The approval or disapproval of this proposal by stockholders will not require the Board of Directors or the Compensation Committee to take any action regarding our executive compensation practices. The final decision on the compensation and benefits of our named executive officers and on whether, and if so, how, to address stockholder disapproval of this proposal remains with the Board of Directors and the Compensation Committee.

Unless the Board of Directors modifies its determination on the frequency of future "say-on-pay" advisory votes, the next "say-on-pay" advisory vote will be held at the 2026 annual meeting of stockholders.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;20

------

[Back to Contents](#_TOC)

## **Item 4. Advisory (Non-Binding) Vote on the Frequency of Future Advisory Votes to Approve Executive Compensation Every 1, 2 or 3 Years** 
**The Board of Directors recommends that you vote for conducting future advisory votes to approve executive compensation EVERY THREE YEARS.**

The Dodd-Frank Act also provides our stockholders with an opportunity to vote on a proposal, on an advisory (non-binding) basis, regarding how frequently we should seek an advisory vote to approve the compensation of our named executive officers, as disclosed pursuant to the Securities and Exchange Commission's compensation disclosure rules, such as Item 3 above. In this Item 4, we are asking stockholders to vote on whether future advisory votes on executive compensation (similar to Item 3) should occur every year, every two years or every three years. Stockholders will be able to specify one of four choices for this proposal on the proxy card: one year, two years, three years or abstain. Stockholders are not voting to approve or disapprove the Board's recommendation. This advisory vote on the frequency of future advisory votes on executive compensation is non-binding on the Board.

The Board understands that there are different views as to what is an appropriate frequency for advisory votes on executive compensation. After careful consideration of this proposal, our Board of Directors has determined that an advisory vote on executive compensation that occurs every THREE YEARS is the most appropriate alternative for the Company, and therefore our Board of Directors recommends that you vote for a three-year interval for the advisory vote on executive compensation.

With respect to this item, if none of the frequency alternatives (one year, two years or three years) receives the affirmative vote of a majority of our Voting Power, we will consider the frequency that receives the highest number of votes by our Voting Power to be the frequency that has been selected by our stockholders. However, because this vote is advisory and not binding on us or our Board of Directors in any way, our Board of Directors may decide that it is in our and our stockholders' best interests to hold an advisory vote on executive compensation more or less frequently than the option approved by our stockholders.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;21

------

[Back to Contents](#_TOC)

## **Item 5. Stockholder Proposal: Political Disclosure** 
**The Board of Directors recommends that you vote AGAINST this Stockholder Proposal: Political Disclosure.**

James McRitchie and Myra K. Young, 9295 Yorkship Court, Elk Grove, CA 95758, beneficial owners of 25 shares of Bio-Rad common stock, have notified Bio-Rad that their designee, John Chevedden, intends to present the following proposal for consideration at the annual meeting. In accordance with the applicable proxy regulations, the text of the stockholder proposal, supporting statement and any graphics are set forth immediately below.

Bio-Rad is not responsible for the content of this stockholder proposal or the accuracy of the supporting statement.

**Stockholder Proposal:**

![](im2326957350x1083985815.jpg)

**Proposal 5 –Political Disclosure**

**Resolved:** James McRitchie, of CorpGov.net, requests Bio-Rad Laboratories Inc. ("Bio-Rad" or "Company") provide a report, updated semiannually, disclosing Bio-Rad's:

1. Policies and procedures for making, with corporate funds or assets, contributions and expenditures (direct or indirect) to (a) participate or intervene in any campaign on behalf of (or in opposition to) any candidate for public office, or (b) influence the general public, or any segment thereof, with respect to an election or referendum.

2. Monetary and non-monetary contributions and expenditures (direct and indirect) used in the manner described in section 1 above, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The identity of the recipient as well as the amount paid to each; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. The title(s) of the person(s) in the Company responsible for decision-making.

The report shall be presented to the board of directors or relevant board committee and posted on Bio-Rad's website within 12 months after the annual meeting. This proposal does not encompass lobbying spending.

**Supporting Statement:** As long-term shareholders of Bio-Rad, we support transparency and accountability in corporate electoral spending. This includes any activity considered intervention in a political campaign under the Internal Revenue Code, such as direct and indirect contributions to political candidates, parties, or organizations, and independent expenditures or electioneering communications on behalf of federal, state, or local candidates.

Political spending can adversely impact a company's reputation, value, and bottom line. The risk is especially serious when involving trade associations, Super PACs, 527 committees, and "social welfare" organizations – groups that routinely pass money to or spend on behalf of candidates and political causes companies might not otherwise support.

The Conference Board's "Under a Microscope"<sup>(1)</sup> details these risks, recommends the process suggested in this proposal, and warns:

a new era of stakeholder scrutiny, social media, and political polarization has propelled corporate political activity—and the risks that come with it—into the spotlight. Political activity can pose increasingly significant risks for companies, including the perception that political contributions—and other forms of activity—are at odds with core company values.

We ask Bio-Rad to disclose all its electoral spending, including payments to trade associations and other tax-exempt organizations, which may be used for electoral purposes–and are otherwise undisclosed. This would bring our Company in line with leading companies, including Becton, Dickinson and Company, Bristol-Myers Squibb Company, and Boston Scientific Corp.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;22

------

[Back to Contents](#_TOC)

Without knowing the recipients of Bio-Rad's political dollars, we cannot assess alignment with its policies on climate change and sustainability or other areas of concern. Bio-Rad is a controlled company with a dual-class structure. It is, therefore, even more critical that the Board hear from independent shareholders on this issue to avoid groupthink and risk. Bio-Rad ranks in the bottom tier for 2022 CPA-Zicklin Index disclosure<sup>(2)</sup>.

(1) https://www.conference-board.org/publications/

(2) https://www.politicalaccountability.net/wp-content/uploads/2022/10/2022-CPA-Zicklin-Index.pdf

**Enhance Shareholder Value, Vote FOR Political Disclosure – Proposal 5**

**<u>Board's</u> <u>Statement</u> <u>in</u> <u>Opposition:</u>**

Bio-Rad's Code of Business Ethics and Conduct prohibits use of the "company's time, funds, or other resources to advance or support any political cause or candidate." Pursuant to these principles, the Company does not intend to make any monetary or non-monetary contributions or expenditures to participate in or intervene in any political campaigns, elections or referendums. Accordingly, the Board of Directors believes that the report described in the stockholder proposal is unnecessary and recommends that you vote AGAINST the stockholder proposal.

**<u>The</u> <u>Board</u> <u>of</u> <u>Directors</u> <u>recommends</u> <u>that</u> <u>you</u> <u>vote</u> <u>AGAINST</u> <u>this</u> <u>stockholder</u> <u>proposal.</u>**

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;23

------

[Back to Contents](#_TOC)

## **Executive Officers** 
Executive officers of Bio-Rad during the period between January 2022 and the date of this proxy statement are listed in the table below.

---

| | | |
|:---|:---|:---|
| **Name** | **Position with Bio-Rad** | **Age** |
| Norman Schwartz | President, Chief Executive Officer and Chairman of the Board | 73 |
| Michael Crowley | Executive Vice President, Global Commercial Operations | 61 |
| Diane Dahowski | Executive Vice President, Global Supply Chain | 61 |
| Ilan Daskal | Executive Vice President and Chief Financial Officer | 57 |
| Timothy S. Ernst | Executive Vice President, General Counsel and Secretary | 63 |
| Dara Grantham Wright | Executive Vice President and President, Clinical Diagnostics Group | 47 |
| Andrew J. Last | Executive Vice President and Chief Operating Officer | 63 |
| Simon May | Executive Vice President and President, Life Science Group | 51 |

---

Biographical information regarding Norman Schwartz is provided in the preceding pages. Biographical information regarding Michael Crowley, Diane Dahowski, Ilan Daskal, Timothy S. Ernst, Dara Grantham Wright, Andrew J. Last, and Simon May, is set forth below.

❯

##### **MICHAEL CROWLEY** 
Michael Crowley was appointed Executive Vice President, Global Commercial Operations in December 2014. Previously he was Vice President, Commercial Manager, Europe from 2012 to 2014 and Commercial Manager, Clinical Diagnostics Group, Europe from 2011 to 2012 and Division Manager of the Clinical Diagnostics Group North American Sales Organization from 2008 to 2011. Prior to that, he was the Clinical Diagnostics U.S. National Sales Manager since joining Bio-Rad in 1998.

❯

##### **DIANE DAHOWSKI** 
Diane Dahowski was appointed Executive Vice President, Global Supply Chain in February 2020. Previously she was Senior Vice President, Global Technology & Systems from 2014 to 2020, and SVP, Clinical Diagnostics Group U.S. Operations from 2008 to 2014. Prior to that she held various positions within Bio-Rad since joining us in 1988, including VP, Clinical Immunology Division, VP Clinical Systems Division, and VP, North America Commercial Operations.

❯

##### **ILAN DASKAL** 
Ilan Daskal was appointed Executive Vice President and Chief Financial Officer in April 2019. Prior to joining Bio-Rad, Mr. Daskal, was the Chief Financial Officer of Lumileds, a global leader in advanced lighting technology, from May 2017 to January 2019. From 2015 through 2016, Mr. Daskal held multiple short-term Chief Financial Officer roles with private and public companies including Aricent Inc., a global design and engineering company, Cepheid, a molecular diagnostic company, and SunEdison Inc., a renewable energy company. Prior to that, from 2008 to 2015, Mr. Daskal was the Executive Vice President and Chief Financial Officer at International Rectifier Corporation, a leader in power management semi-conductor technology that was publicly traded until it was acquired by Infineon Technologies in 2015.

❯

##### **TIMOTHY S. ERNST** 
Timothy S. Ernst was appointed Executive Vice President, General Counsel and Secretary in June 2016. Previously he was Senior Vice President, General Counsel and Secretary of Big Heart Pet Brands, a manufacturer and marketer of branded pet food products, from 2014 to 2015. Prior to that, he was the Senior Vice-President, General Counsel and Secretary of Del Monte Foods, a manufacturer and marketer of consumer food products, from 2012 to 2014, and Associate General Counsel and Assistant Secretary of Del Monte Foods from 1995 to 2012. He was the Associate General Counsel of California and Hawaiian Sugar Company, a refiner and marketer of sugar and sugar products, from 1990 to 1995. He is a member of the California Bar and Association of Corporate Counsel.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;24

------

[Back to Contents](#_TOC)

❯

##### **DARA GRANTHAM WRIGHT** 
Dara Grantham Wright was appointed Executive Vice President, President, Clinical Diagnostics Group in January 2020. Prior to joining Bio-Rad, from 2016 to November 2019 Ms. Grantham Wright was Vice President and General Manager, Biosciences Division, Life Science Solutions Group, Protein & Cell Analysis at Thermo Fisher Scientific Inc., a biotechnology product development company. From 2014 to 2016, Ms. Grantham Wright was Senior Vice President & General Manager, eBioscience Business Unit at Affymetrix, Inc., a manufacturer of DNA microarrays that was acquired by Thermo Fisher Scientific in 2016. Prior to that, from 2013 to 2014, she was Chief Commercial Officer at Boreal Genomics, Inc., a company that develops new technologies for blood-based detection and monitoring of circulating tumor DNA. From 2010 to 2013 she was Global Vice President of Strategic Marketing and Clinical Applications at Affymetrix, Inc.

❯

##### **ANDREW J. LAST** 
Andrew J. Last was appointed Executive Vice President and Chief Operating Officer in April 2019. Prior to joining Bio-Rad, Dr. Last was the Chief Commercial Officer of Berkeley Lights, Inc., a digital cell biology company that develops and commercializes platforms for the acceleration of discovery, development and delivery of cell-based products and therapies, from December 2017 to April 2019. From 2016 through 2017, Dr. Last was the Chief Operating Officer of Intrexon Corporation, a publicly traded biotechnology company. Prior to that, from 2010 to 2016, Dr. Last held senior roles at Affymetrix, Inc., a company that manufactures DNA microarray solutions, including most recently the role of Executive Vice President and Chief Operating Officer. Dr. Last's other previous global leadership roles have included senior positions with Becton, Dickinson and Company from 2004 to 2010; Applied Biosystems from 2002 to 2004; Incyte Genomics from 1999 to 2002; and Monsanto Company from 1987 to 1999. Dr. Last also currently serves on the Board of Directors of OncoCyte Corporation, a publicly traded molecular diagnostics company.

❯

##### **SIMON MAY** 
Simon May was appointed Executive Vice President, President, Life Science Group in January 2022. Previously Dr. May was Senior Vice President and General Manager of the Digital Biology Group from 2020 to 2022, Senior Vice President, Commercial Manager from 2015 to 2020, and Vice President, North American Sales from 2014 to 2015. Prior to joining Bio-Rad in 2014, Dr. May held various leadership roles in sales and product/portfolio management at Thermo Fisher Scientific Inc., a biotechnology product development company, from 2004 to 2014. He holds a PhD in Molecular Biology and acquired hands-on expertise in molecular biology and tissue culture techniques as a Postdoctoral Research Fellow at the University of Liverpool.

Our executive officers also serve in various management capacities with our wholly owned subsidiaries.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;25

------

[Back to Contents](#_TOC)

## **Principal and Management Stockholders** 
The following table presents certain information as of February 24, 2023 (except as noted below), with respect to our Class A Common Stock and Class B Common Stock beneficially owned by: (i) any person who is known to us to be the beneficial owner of more than five percent of the outstanding Common Stock of either class, (ii) each of our directors and our director nominees, (iii) certain of our executive officers named in the "Summary Compensation Table" of this proxy statement and (iv) all of our directors and executive officers as a group. The address for all executive officers and directors is c/o Bio-Rad Laboratories, Inc., 1000 Alfred Nobel Drive, Hercules, California, 94547.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name and, with Respect to** <br> **Owner of 5% or More, Address**  | **Class A Common Stock<sup>(1)</sup>** | **Class A Common Stock<sup>(1)</sup>** | **Class B Common Stock** | **Class B Common Stock** |
| **Name and, with Respect to** <br> **Owner of 5% or More, Address**  | **Number of Shares and** <br> **Nature of Ownership<sup>(2)</sup>** | **Percent** <br>**of Class** | **Number of Shares and** <br> **Nature of Ownership<sup>(2)</sup>** | **Percent** <br>**of Class** |
| &nbsp;&nbsp;&nbsp;Blue Raven Partners, L.P.<sup>(3)</sup> <br> 1000 Alfred Nobel Drive <br>Hercules, CA 94547<br>|  | 0.0% | 4060054 | 80.0% |
| &nbsp;&nbsp;&nbsp;The Vanguard Group<sup>(4)</sup> <br> 100 Vanguard Blvd. <br>Malvern, PA 19355<br>| 2391436 | 9.8% |  | 0.0% |
| &nbsp;&nbsp;&nbsp;Blackrock, Inc.<sup>(5)</sup> <br> 55 East 52nd Street <br>New York, NY 10055<br>| 1582313 | 6.5% |  | 0.0% |
| &nbsp;&nbsp;&nbsp;Alice N. Schwartz<sup>(6)(7)(8)(9)</sup><br> Bio-Rad Laboratories, Inc. 1000 Alfred <br> Nobel Drive Hercules, CA 94547<br>| 2734673 | 11.2% | 4555200 | 89.8% |
| &nbsp;&nbsp;&nbsp;Norman Schwartz<sup>(6)(8)(9)(10)(11)</sup><br> Bio-Rad Laboratories, Inc. <br>1000 Alfred Nobel Drive <br>Hercules, CA 94547<br>| 476362 | 1.9% | 4509643 | 87.1% |
| &nbsp;&nbsp;&nbsp;Steven Schwartz<sup>(6)(8)(9)(12)</sup><br> Bio-Rad Laboratories, Inc. <br>1000 Alfred Nobel Drive <br>Hercules, CA 94547<br>| 377249 | 1.5% | 4098082 | 80.8% |
| Jeffrey L. Edwards |  | 0.0% |  | 0.0% |
| Gregory K. Hinckley | 500 | 0.0% |  | 0.0% |
| Melinda Litherland |  | 0.0% |  | 0.0% |
| Arnold A. Pinkston |  | 0.0% |  | 0.0% |
| Allison Schwartz<sup>(8)(9)</sup> | 14312 | 0.1% | 3890 | 0.1% |
| Ilan Daskal<sup>(10)</sup> | 4133 | 0.0% |  | 0.0% |
| Dara Grantham Wright<sup>(10)</sup> | 4553 | 0.0% |  | 0.0% |
| Andrew J. Last<sup>(10)</sup> | 6550 | 0.0% |  | 0.0% |
| Simon May<sup>(10)</sup> | 1582 | 0.0% |  | 0.0% |
| All directors and executive officers as a group<sup>(10)(13)</sup> (13 persons) | 535209 | 2.2% | 4513533 | 87.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Excludes Class A Common Stock that may be acquired on conversion of Class B Common Stock. Class B Common Stock may be converted to Class A Common Stock on a one for one basis and, if fully converted, would result in the following percentage beneficial ownership of Class A Common Stock: Blue Raven Partners. L.P. 13.7%; The Vanguard Group, 8.1%; BlackRock, Inc. 5.3%; Alice N. Schwartz 24.6%; Norman Schwartz 16.8%; Steven Schwartz 15.1%; Allison Schwartz 0.1%; and all directors and executive officers as a group 17.0%. Management considers any substantial conversions by the executive officers or directors listed in the table to be highly unlikely.<br>(2) Except as otherwise indicated and subject to applicable community property and similar statutes, the persons listed as beneficial owners of the shares have sole voting and investment power with respect to such shares. Number of shares is based on the statements of the stockholders where not identified specifically in the stockholder register.<br>(3) Alice N. Schwartz, Norman Schwartz and Steven Schwartz are general partners of Blue Raven Partners, L.P., a California limited partnership, and, as such, share voting and dispositive power over the Class B Common Stock held by Blue Raven Partners.<br>(4) Based solely on a Schedule 13G/A filed on February 9, 2023 with the Securities and Exchange Commission pursuant to Rule 13d-1(b) of the Exchange Act.<br>(5) Based solely on a Schedule 13G/A filed on February 1, 2023 with the Securities and Exchange Commission pursuant to Rule 13d-1(b) of the Exchange Act. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Excludes Class A Common Stock that may be acquired on conversion of Class B Common Stock. Class B Common Stock may be converted to Class A Common Stock on a one for one basis and, if fully converted, would result in the following percentage beneficial ownership of Class A Common Stock: Blue Raven Partners. L.P. 13.7%; The Vanguard Group, 8.1%; BlackRock, Inc. 5.3%; Alice N. Schwartz 24.6%; Norman Schwartz 16.8%; Steven Schwartz 15.1%; Allison Schwartz 0.1%; and all directors and executive officers as a group 17.0%. Management considers any substantial conversions by the executive officers or directors listed in the table to be highly unlikely.<br>(2) Except as otherwise indicated and subject to applicable community property and similar statutes, the persons listed as beneficial owners of the shares have sole voting and investment power with respect to such shares. Number of shares is based on the statements of the stockholders where not identified specifically in the stockholder register.<br>(3) Alice N. Schwartz, Norman Schwartz and Steven Schwartz are general partners of Blue Raven Partners, L.P., a California limited partnership, and, as such, share voting and dispositive power over the Class B Common Stock held by Blue Raven Partners.<br>(4) Based solely on a Schedule 13G/A filed on February 9, 2023 with the Securities and Exchange Commission pursuant to Rule 13d-1(b) of the Exchange Act.<br>(5) Based solely on a Schedule 13G/A filed on February 1, 2023 with the Securities and Exchange Commission pursuant to Rule 13d-1(b) of the Exchange Act. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Excludes Class A Common Stock that may be acquired on conversion of Class B Common Stock. Class B Common Stock may be converted to Class A Common Stock on a one for one basis and, if fully converted, would result in the following percentage beneficial ownership of Class A Common Stock: Blue Raven Partners. L.P. 13.7%; The Vanguard Group, 8.1%; BlackRock, Inc. 5.3%; Alice N. Schwartz 24.6%; Norman Schwartz 16.8%; Steven Schwartz 15.1%; Allison Schwartz 0.1%; and all directors and executive officers as a group 17.0%. Management considers any substantial conversions by the executive officers or directors listed in the table to be highly unlikely.<br>(2) Except as otherwise indicated and subject to applicable community property and similar statutes, the persons listed as beneficial owners of the shares have sole voting and investment power with respect to such shares. Number of shares is based on the statements of the stockholders where not identified specifically in the stockholder register.<br>(3) Alice N. Schwartz, Norman Schwartz and Steven Schwartz are general partners of Blue Raven Partners, L.P., a California limited partnership, and, as such, share voting and dispositive power over the Class B Common Stock held by Blue Raven Partners.<br>(4) Based solely on a Schedule 13G/A filed on February 9, 2023 with the Securities and Exchange Commission pursuant to Rule 13d-1(b) of the Exchange Act.<br>(5) Based solely on a Schedule 13G/A filed on February 1, 2023 with the Securities and Exchange Commission pursuant to Rule 13d-1(b) of the Exchange Act. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Excludes Class A Common Stock that may be acquired on conversion of Class B Common Stock. Class B Common Stock may be converted to Class A Common Stock on a one for one basis and, if fully converted, would result in the following percentage beneficial ownership of Class A Common Stock: Blue Raven Partners. L.P. 13.7%; The Vanguard Group, 8.1%; BlackRock, Inc. 5.3%; Alice N. Schwartz 24.6%; Norman Schwartz 16.8%; Steven Schwartz 15.1%; Allison Schwartz 0.1%; and all directors and executive officers as a group 17.0%. Management considers any substantial conversions by the executive officers or directors listed in the table to be highly unlikely.<br>(2) Except as otherwise indicated and subject to applicable community property and similar statutes, the persons listed as beneficial owners of the shares have sole voting and investment power with respect to such shares. Number of shares is based on the statements of the stockholders where not identified specifically in the stockholder register.<br>(3) Alice N. Schwartz, Norman Schwartz and Steven Schwartz are general partners of Blue Raven Partners, L.P., a California limited partnership, and, as such, share voting and dispositive power over the Class B Common Stock held by Blue Raven Partners.<br>(4) Based solely on a Schedule 13G/A filed on February 9, 2023 with the Securities and Exchange Commission pursuant to Rule 13d-1(b) of the Exchange Act.<br>(5) Based solely on a Schedule 13G/A filed on February 1, 2023 with the Securities and Exchange Commission pursuant to Rule 13d-1(b) of the Exchange Act. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Excludes Class A Common Stock that may be acquired on conversion of Class B Common Stock. Class B Common Stock may be converted to Class A Common Stock on a one for one basis and, if fully converted, would result in the following percentage beneficial ownership of Class A Common Stock: Blue Raven Partners. L.P. 13.7%; The Vanguard Group, 8.1%; BlackRock, Inc. 5.3%; Alice N. Schwartz 24.6%; Norman Schwartz 16.8%; Steven Schwartz 15.1%; Allison Schwartz 0.1%; and all directors and executive officers as a group 17.0%. Management considers any substantial conversions by the executive officers or directors listed in the table to be highly unlikely.<br>(2) Except as otherwise indicated and subject to applicable community property and similar statutes, the persons listed as beneficial owners of the shares have sole voting and investment power with respect to such shares. Number of shares is based on the statements of the stockholders where not identified specifically in the stockholder register.<br>(3) Alice N. Schwartz, Norman Schwartz and Steven Schwartz are general partners of Blue Raven Partners, L.P., a California limited partnership, and, as such, share voting and dispositive power over the Class B Common Stock held by Blue Raven Partners.<br>(4) Based solely on a Schedule 13G/A filed on February 9, 2023 with the Securities and Exchange Commission pursuant to Rule 13d-1(b) of the Exchange Act.<br>(5) Based solely on a Schedule 13G/A filed on February 1, 2023 with the Securities and Exchange Commission pursuant to Rule 13d-1(b) of the Exchange Act. |

---

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;26

------

[Back to Contents](#_TOC)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) Includes 4,060,054 shares of Class B Common Stock held by Blue Raven Partners, L.P.<br>(7) Includes 2,721,388 shares of Class A Common Stock and 495,146 shares of Class B Common Stock, which are held in the following trusts, all of which Alice N. Schwartz is the sole trustee: the David and Alice N. Schwartz Charitable Remainder Unitrust (34,311 shares of Class A Common Stock); the David Schwartz Exemption Trust (90 shares of Class A Common Stock); the David Schwartz Exempt Marital Trust (240 shares of Class A Common Stock); the David Schwartz Non-Exempt Marital Trust (898,931 shares of Class A Common Stock and 57,000 shares of Class B Common Stock); the Alice N. Schwartz Revocable Trust (1,787,816 shares of Class A Common Stock and 438,146 shares of Class B Common Stock).<br>(8) Includes 13,285 shares of Class A Common Stock held by Alles Institute for Medical Research, a Delaware Charitable Nonstock Corporation, with respect to which Alice N. Schwartz, Norman Schwartz, Steven Schwartz and Allison Schwartz each have voting power and dispositive power consistent with the purposes of the Delaware Charitable Nonstock Corporation.<br>(9) Norman Schwartz and Steven Schwartz are sons of Alice N. Schwartz. Norman Schwartz is the father of Allison Schwartz.<br>(10) Includes shares with respect to which such persons have the right to acquire beneficial ownership immediately or within sixty days of February 24, 2023 under the Company's employee stock purchase plan, restricted stock unit agreements and stock option agreements, as follows: Norman Schwartz, 35,233 Class A shares and 105,000 Class B shares; Ilan Daskal, 3,135 Class A shares; Dara Grantham Wright, 2,791 Class A shares; Andrew J. Last, 3,458 Class A shares; Simon May, 32 Class A shares; and all directors and officers as a group, 64,809 Class A shares and 105,000 Class B shares.<br>(11) Includes 12,900 shares of Class B Common Stock owned by Norman Schwartz's wife, as to which Norman Schwartz disclaims any beneficial ownership.<br>(12) Includes 1,818 shares of Class A Common Stock and 12,900 shares of Class B Common Stock owned by Steven Schwartz's wife, as to which Steven Schwartz disclaims any beneficial ownership.<br>(13) As a Director Emeritus, Alice N. Schwartz is not included in "All directors and executive officers as a group."<br>

## **Compensation Committee Report** 
The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis with management, including the Company's Chairman and President and Chief Executive Officer. Based on the review and discussions referred to above, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in the annual report on Form 10-K for the fiscal year ended December 31, 2022 and this proxy statement.

THE COMPENSATION COMMITTEE Jeffrey L. Edwards Gregory K. Hinckley <br>

The Compensation Committee report shall not be deemed "soliciting material" or incorporated by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act or the Exchange Act and shall not otherwise be deemed filed under these Acts.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;27

------

[Back to Contents](#_TOC)

## **Compensation Discussion and Analysis** 
In this Compensation Discussion and Analysis, we review the objectives and elements of our execution compensation program and discuss the 2022 compensation earned by our named executive officers, or NEOs.

For 2022, our named executive officers were:

---

| | |
|:---|:---|
| **Name** | **Position** |
| Norman Schwartz | President, Chief Executive Officer and Chairman of the Board |
| Ilan Daskal | Executive Vice President and Chief Financial Officer |
| Andrew J. Last | Executive Vice President Chief Operating Officer |
| Dara Grantham Wright | Executive Vice President and President, Clinical Diagnostics Group |
| Simon May | Executive Vice President and President, Life Science Group |

---

### COMPENSATION PROGRAM OBJECTIVES AND PHILOSOPHY
We maintain various compensation programs for our named executive officers. Our executive compensation program, taken as a whole, has several objectives. The overriding objective of our executive compensation program is to attract, retain, motivate and develop the type of executives who will establish and execute strategic initiatives that help us to continue to grow a profitable business. We also want our executive compensation program to help align the interests of the executives with the interests of the Company and its stockholders. Finally, we want to reward our executives for business achievements and satisfaction of corporate objectives without creating risks which could have a material adverse effect on the Company.

In developing our overall executive compensation program and in setting individual pay levels for the named executive officers, we strive to meet the following goals:

• To pay salaries that are competitive in our industry and our geographical market.

• To use executive pay practices that are commonly found in our industry, as appropriate.

• To pay salaries and award merit increases on the basis of the individual executive's performance and contributions and the value of the executive's position within our organization.

• To maintain a "pay for performance" outlook, particularly in our incentive programs.

• To manage risk taking by incorporating objective company performance goals into our incentive programs.

Our executive compensation program is designed to reward our executives for Company and individual performance. Because we feel that each of our named executive officers provides unique services to us, we do not use a fixed relationship between base pay, annual performance-based cash bonus payments and equity awards. When we make our final decisions about a named executive officer's total compensation package for a year, we look at the three primary elements of compensation (base pay, potential performance-based bonus payments and equity awards) individually and as a complete package. Overall, we believe that our total compensation program for executives is reasonable while being competitive within the market in which we compete for executive talent and does not create risks that are reasonably likely to have a material adverse effect on the Company.

### STOCKHOLDER SAY-ON-PAY VOTE
At our 2020 meeting of stockholders, we provided our stockholders with the opportunity to cast an advisory vote on executive compensation. 97% of the shares represented in attendance or by proxy and entitled to vote on this "2020 say-on-pay vote" were voted in favor of the proposal. We have considered the 2020 say-on-pay vote, and we believe that the substantial support of our stockholders for the 2020 say-on-pay vote proposal indicates that our stockholders are generally supportive of our approach to executive compensation. Thus, we have not made any material changes to our executive compensation arrangements in response to the 2020 say-on-pay vote. At our 2017 meeting of stockholders, our stockholders voted in favor of the proposal to hold say-on-pay votes every three years. Accordingly, the next say-on-pay advisory vote will be held this year at our 2023 meeting of stockholders. We will also hold an advisory vote this year at our 2023 meeting of stockholders concerning the frequency of the say-on-pay advisory vote. In the future, we will continue to consider the outcome of our say-on-pay votes when making compensation decisions regarding the named executive officers.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;28

------

[Back to Contents](#_TOC)

### THE COMPONENTS OF OUR EXECUTIVE COMPENSATION PROGRAM
To achieve the above goals, we have created an executive compensation program which consists of base pay, a short-term performance-based cash bonus program pursuant to the Incentive Bonus Plan, or IBP, and an equity grant program providing long-term incentives.

---

| | | | |
|:---|:---|:---|:---|
|  | **** | **Pay Element** | **Objective** |
| **FIXED** | Annual | **Base Salary** | &nbsp;&nbsp;• Provides a degree of financial certainty and stability that helps us retain talent.<br>• Recognizes competitive market conditions and/or rewards individual performance through periodic increases.<br>|
| **AT RISK OR PERFORMANCE-BASED** | Long-Term | **Restricted Stock Units and Performance Stock Units** | &nbsp;&nbsp;• Provides a direct link to the creation of stockholder value and execution of our strategy.<br>• Aligns NEOs' interests with stockholders.<br>• Fosters long-term focus and retention.<br>|
| **AT RISK OR PERFORMANCE-BASED** | Annual | **Incentive Bonus Plan (IBP)** | &nbsp;&nbsp;• Motivates NEOs to meet or exceed our annual performance goals to drive annual performance and position us for longer-term success.<br>• Measures NEOs' performance against pre-established Company performance goals.<br>• Aligns all staff members around the same Company performance goals as all such annual cash incentive awards are based on the same Company financial performance goals.<br>|
| **AT RISK OR PERFORMANCE-BASED** |  |  |  |

---

We use this mix of compensation types for a variety of reasons:

• These types of programs, as a package, are typically offered by the companies from which we seek executive talent.

• These programs provide immediate and long-term incentives for the executive officers, thereby helping to align the executives' interests with those of the Company and its stockholders.

• We apply differing performance goals to the various types of pay to help motivate the executives to accomplish separate and diverse corporate and individual goals.

• Diverse programs, performance goals and payout timing help manage risk taking.

We provide executives with a package of fringe benefits on the same basis that is provided to all full-time benefits eligible employees. These benefits include such items as health insurance, tax qualified profit sharing plan contributions and group term life insurance. We do not provide the executives with any benefits that are not generally available to other full-time professional employees, other than the benefits provided to participants under the Executive Change in Control Severance Plan adopted in February 2022, which are described in this proxy statement under the heading "Potential Payments Upon Termination or Change in Control."

We believe that our executive compensation program, taken as a whole, is a cost-effective method of providing competitive pay to our named executive officers and implementing our compensation philosophy and objectives.

### OUR PROCESS FOR SETTING EXECUTIVE COMPENSATION
Our Human Resources Department provides various types of compensation information to the President/Chief Executive Officer and to the Compensation Committee for their consideration and reference. The Compensation Committee's focus is on the compensation of the President/Chief Executive Officer and the incentive bonus and equity awards of the named executive officers.

The President/Chief Executive Officer determines the base pay for the other named executive officers. Our process for setting executive compensation is described below.

❯

##### **BASE PAY** 
In connection with setting levels of base pay, our Human Resources Department reviews independently published surveys of executive compensation levels, which cover over 1,000 U.S. based companies varying in size and industry and prepares a report summarizing their findings. In 2022, Compensia, Inc. acted as a compensation advisor to our Compensation Committee. In 2022, our Human Resources Department also reviewed data from the Radford Technology Survey, which provides data from a wide range of technology sub-industries, and Main Data Group, Inc., which provides compensation information for executive positions in publicly traded peer companies. From this information, our Human Resources Department determined the market salary at the median level for each comparable executive position. In addition, we review the compensation of a smaller

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;29

------

[Back to Contents](#_TOC)

group of companies in industry sectors in which we compete to provide additional guidance in setting base pay. This group consists of the companies in our peer group. We consider a number of potential criteria to determine which companies to include in our peer group, including companies in our industry of comparable size as measured by sales, market capitalization or asset base, in our geographic proximity, and with whom we compete for employee talent.

In 2022 the companies we considered comprising our peer group were:

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;• Agilent Technologies Inc.<br>| &nbsp;&nbsp;&nbsp;• LivaNova PLC <br>|
| &nbsp;&nbsp;&nbsp;• Bruker Corporation<br>| &nbsp;&nbsp;&nbsp;• Mettler-Toledo International Inc.<br>|
| &nbsp;&nbsp;&nbsp;• Charles River Laboratories, Inc.<br>| &nbsp;&nbsp;&nbsp;• NuVasive, Inc.<br>|
| &nbsp;&nbsp;&nbsp;• The Cooper Companies Inc.<br>| &nbsp;&nbsp;&nbsp;• PerkinElmer, Inc.<br>|
| &nbsp;&nbsp;&nbsp;• Dentsply Sirona, Inc.<br>| &nbsp;&nbsp;&nbsp;• Quidel Corporation<br>|
| &nbsp;&nbsp;&nbsp;• Hologic, Inc.<br>| &nbsp;&nbsp;&nbsp;• Qiagen N.V.<br>|
| &nbsp;&nbsp;&nbsp;• IDEXX Laboratories, Inc.<br>| &nbsp;&nbsp;&nbsp;• ResMed Inc.<br>|
| &nbsp;&nbsp;&nbsp;• Illumina, Inc.<br>| &nbsp;&nbsp;&nbsp;• Steris Corporation<br>|
| &nbsp;&nbsp;&nbsp;• Integer Holdings Corporation<br>| &nbsp;&nbsp;&nbsp;• Teleflex Incorporated<br>|
| &nbsp;&nbsp;&nbsp;• Integra LifeSciences Holdings Corporation<br>| &nbsp;&nbsp;&nbsp;• Waters Corporation<br>|
| &nbsp;&nbsp;&nbsp;• Intuitive Surgical, Inc.<br>| &nbsp;&nbsp;&nbsp;• West Pharmaceutical Services, Inc.<br>|

---

The 2022 peer group was modified relative to our 2021 peer group as follows: The following six companies were removed: Edwards Lifesciences Corporation, Hill-Rom Holdings, Inc., ICON plc, PRA Health Sciences, Inc., Syneos Health, Inc. and Varian Medical Systems, Inc. The following four companies were added: The Cooper Companies Inc., Dentsply Sirona Inc., Quidel Corporation, and West Pharmaceutical Services, Inc. The 2022 peer group includes twenty-two life sciences and medical products companies with $1 to $5 billion in annual revenues in order to include companies that were of similar size and in similar industries to the Company. The modifications to the peer group were made to more closely align the size and industry of the peer group companies to the size and industry of the Company.

Our Human Resources Department reviews this information with the President/Chief Executive Officer, and with respect to the President/Chief Executive Officer directly with the Compensation Committee, who then decide at their discretion if the individual base pay levels of executives need to be adjusted. Our Compensation Committee does not see any of the individual companies in the surveys, except for the companies within our peer group with respect to our President/Chief Executive Officer's base pay. Other factors considered in determining base pay, in addition to the survey and peer group information presented by the Human Resources Department, are:

• The financial position of the Company compared to the previous year;

• General economic conditions both nationally and in the local market of our corporate office;

• The executive's achievement of individual performance goals established for the year; and

• Where the executive's current base pay falls relative to survey data and other company executives.

Based on all of the factors outlined above, as well as the market data, the Compensation Committee, in the case of the President/Chief Executive Officer, and the President/Chief Executive Officer, for the other named executive officers, determine the named executive officer's base pay for the following year, and thus any of these criteria could materially impact the named executive officer's base pay.

In 2022, each of our named executive officers received a merit increase to his/her base pay based on the factors described above. These increases ranged from 4% to 15.85% of base pay and were effective as of April 1, 2022, except for Dr. May's salary increase, which was effective January 4, 2022 when he became an executive officer. As a result, our named executive officers' annual base salaries effective April 1, 2022 were as follows: Mr. Schwartz: $1,040,000; Mr. Daskal: $596,500; Dr. Last $646,000; Ms. Grantham Wright: $546,009; and Dr. May: $500,000.

❯

##### **INCENTIVE BONUS PLAN, OR IBP (CASH-BASED INCENTIVE PROGRAM)** 
All of our named executive officers participate in our company-wide annual cash bonus program, which is known as the Incentive Bonus Plan, or IBP. The plan, which covers all of the named executive officers, as well as other employees, operates on a calendar year basis. At the beginning of the year, objective performance metrics in areas of achievement are determined and approved by executive management. In 2022 the metrics were:

• Global Sales;

• Profit expressed as global operating income (OI); and

• A group metric objective.

Depending on which part of our organization an employee works, these metrics are applied at the company-wide or Corporate level, or at a combination of the Corporate and business group levels. The bonuses of all our named executive officers were based on the following weighting of these metrics: Corporate Sales (50%), Corporate OI (30%) and a Group metric objective relating to deployment of sales and operations planning ("S&OP") (20%).

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;30

------

[Back to Contents](#_TOC)

The following table shows our financial goals under the IBP for fiscal 2022 relevant to our named executive officers for Corporate and Group Metric goals, and our performance compared to those goals (in millions):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | | **IBP** <br> **Target Plan**  | **Adjusted** <br>**Target Plan<sup>(1)</sup>** | **Actual**  | **Adjusted** <br>**Results<sup>(2)</sup>** | **% of** <br>**Target<sup>(3)</sup>** |
| Corporate Goals | Sales | $2927.5 | $2842.4 | $2802.2 | $2797.2 | 98.4% |
|  | Operating Income (OI)  | $531.8 | $509.6 | $482.6 | $478.1 | 93.8% |
| Group Metric Goals | S&OP Deployment | 100% | 100% | 100.0% | 100.0% | 100.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;(1) We have the ability to modify the goals after the beginning of a year, particularly in response to an unforeseen change in business conditions that makes an established goal irrelevant or inappropriate, subject to the approval of our Chief Executive Officer. In 2022, we adjusted our IBP Target Plan Corporate Sales goal and IBP Target Plan Corporate OI goal to account for the effect of foreign currency.<br>(2) We also have the ability to modify the calculation of the achievement of the results after the beginning of a year, particularly in response to an unforeseen change in business conditions, subject to the approval of our Chief Executive Officer. In 2022, we modified the Sales achievement and the OI achievement to account for certain legal matters, restructurings, and corrections to certain accounting policies.<br>(3) Includes the effects of the adjustments and achieved results for our named executive officers as described in footnotes 2 and 3 above. | &nbsp;&nbsp;&nbsp;&nbsp;(1) We have the ability to modify the goals after the beginning of a year, particularly in response to an unforeseen change in business conditions that makes an established goal irrelevant or inappropriate, subject to the approval of our Chief Executive Officer. In 2022, we adjusted our IBP Target Plan Corporate Sales goal and IBP Target Plan Corporate OI goal to account for the effect of foreign currency.<br>(2) We also have the ability to modify the calculation of the achievement of the results after the beginning of a year, particularly in response to an unforeseen change in business conditions, subject to the approval of our Chief Executive Officer. In 2022, we modified the Sales achievement and the OI achievement to account for certain legal matters, restructurings, and corrections to certain accounting policies.<br>(3) Includes the effects of the adjustments and achieved results for our named executive officers as described in footnotes 2 and 3 above. | &nbsp;&nbsp;&nbsp;&nbsp;(1) We have the ability to modify the goals after the beginning of a year, particularly in response to an unforeseen change in business conditions that makes an established goal irrelevant or inappropriate, subject to the approval of our Chief Executive Officer. In 2022, we adjusted our IBP Target Plan Corporate Sales goal and IBP Target Plan Corporate OI goal to account for the effect of foreign currency.<br>(2) We also have the ability to modify the calculation of the achievement of the results after the beginning of a year, particularly in response to an unforeseen change in business conditions, subject to the approval of our Chief Executive Officer. In 2022, we modified the Sales achievement and the OI achievement to account for certain legal matters, restructurings, and corrections to certain accounting policies.<br>(3) Includes the effects of the adjustments and achieved results for our named executive officers as described in footnotes 2 and 3 above. | &nbsp;&nbsp;&nbsp;&nbsp;(1) We have the ability to modify the goals after the beginning of a year, particularly in response to an unforeseen change in business conditions that makes an established goal irrelevant or inappropriate, subject to the approval of our Chief Executive Officer. In 2022, we adjusted our IBP Target Plan Corporate Sales goal and IBP Target Plan Corporate OI goal to account for the effect of foreign currency.<br>(2) We also have the ability to modify the calculation of the achievement of the results after the beginning of a year, particularly in response to an unforeseen change in business conditions, subject to the approval of our Chief Executive Officer. In 2022, we modified the Sales achievement and the OI achievement to account for certain legal matters, restructurings, and corrections to certain accounting policies.<br>(3) Includes the effects of the adjustments and achieved results for our named executive officers as described in footnotes 2 and 3 above. | &nbsp;&nbsp;&nbsp;&nbsp;(1) We have the ability to modify the goals after the beginning of a year, particularly in response to an unforeseen change in business conditions that makes an established goal irrelevant or inappropriate, subject to the approval of our Chief Executive Officer. In 2022, we adjusted our IBP Target Plan Corporate Sales goal and IBP Target Plan Corporate OI goal to account for the effect of foreign currency.<br>(2) We also have the ability to modify the calculation of the achievement of the results after the beginning of a year, particularly in response to an unforeseen change in business conditions, subject to the approval of our Chief Executive Officer. In 2022, we modified the Sales achievement and the OI achievement to account for certain legal matters, restructurings, and corrections to certain accounting policies.<br>(3) Includes the effects of the adjustments and achieved results for our named executive officers as described in footnotes 2 and 3 above. | &nbsp;&nbsp;&nbsp;&nbsp;(1) We have the ability to modify the goals after the beginning of a year, particularly in response to an unforeseen change in business conditions that makes an established goal irrelevant or inappropriate, subject to the approval of our Chief Executive Officer. In 2022, we adjusted our IBP Target Plan Corporate Sales goal and IBP Target Plan Corporate OI goal to account for the effect of foreign currency.<br>(2) We also have the ability to modify the calculation of the achievement of the results after the beginning of a year, particularly in response to an unforeseen change in business conditions, subject to the approval of our Chief Executive Officer. In 2022, we modified the Sales achievement and the OI achievement to account for certain legal matters, restructurings, and corrections to certain accounting policies.<br>(3) Includes the effects of the adjustments and achieved results for our named executive officers as described in footnotes 2 and 3 above. | &nbsp;&nbsp;&nbsp;&nbsp;(1) We have the ability to modify the goals after the beginning of a year, particularly in response to an unforeseen change in business conditions that makes an established goal irrelevant or inappropriate, subject to the approval of our Chief Executive Officer. In 2022, we adjusted our IBP Target Plan Corporate Sales goal and IBP Target Plan Corporate OI goal to account for the effect of foreign currency.<br>(2) We also have the ability to modify the calculation of the achievement of the results after the beginning of a year, particularly in response to an unforeseen change in business conditions, subject to the approval of our Chief Executive Officer. In 2022, we modified the Sales achievement and the OI achievement to account for certain legal matters, restructurings, and corrections to certain accounting policies.<br>(3) Includes the effects of the adjustments and achieved results for our named executive officers as described in footnotes 2 and 3 above. |

---

We believe these performance metrics promote a strong link between employee contribution and overall company performance. By rewarding employees for meeting and exceeding goals for sales, global operating income and a group metric objective, we motivate them to improve the Company's performance.

The IBP makes a payout only if threshold levels equal to 95% of the sales goals, and/or 90% of the operating income goals, and/or 50% of the group metric objective are satisfied. In order for the group metric objective to be paid, the threshold level of corporate operating income must be achieved. If the sales, and/or operating income, and/or group metric objective goal is met, the named executive officers as well as other IBP participants receive a payment indexed to a percentage of their base pay, based on the achievement relative to each of the established metrics. The percentage of base pay which can be awarded varies based upon job position/salary grade. In 2022 the target bonuses for our named executive officers as a percentage of their base pay were as follows: Mr. Schwartz: 125% (increased from 115% in 2021); Mr. Daskal: 75% (increased from 65% in 2021); Dr. Last: 85% (increased from 80% in 2021); Ms. Grantham Wright: 70% (increased from 55% in 2021); and Dr. May: 70% (increased from 55% in 2021). The payments under this program can be as much as twice the target bonus, but the named executive officers (as well as the other people who participate in the IBP) will not receive this benefit unless we meet the minimum required performance goals for each performance measure.

The IBP also has an individual component, which allows managers to adjust the calculated financial award upward or downward by up to 20%, based on a manager's assessment of the contribution of the participant and of the participant's small team toward the financial results that the Company achieves. In 2022, the IBP awards for all named executive officers were not adjusted for this individual component of the IBP.

With respect to bonuses awarded for 2022, our named executive officers achieved 86.8% of their target bonus opportunity. Payments are typically made during the first quarter of the following year.

We establish the individual target bonus levels, in part, by reviewing competitive market data of companies in our peer group described above. The individual target bonus levels for our named executive officers in 2022 are set forth in the "Grants of Plan-Based Awards Table," and the bonuses paid to our named executive officers under the 2022 IBP are set forth in the "Non-Equity Incentive Plan Compensation" column of the "Summary Compensation Table."

Our Company also reserves the right to award discretionary bonus payments to employees. No such payments were made to any of the named executive officers in the last year.

❯

##### **EQUITY COMPENSATION** 
Another key component of our executive compensation program is equity grants. We make grants of restricted stock units and performance stock units to the named executive officers, as well as other employees, under our 2017 Incentive Award Plan.

In 2022, we granted Class A common stock performance stock units ("PSUs") and Class A common stock restricted stock units ("RSUs") to our named executive officers. Prior to 2022, our named executive officers were granted non-qualified stock options instead of PSUs. We generally granted options to purchase Class A Common Stock and Class A Common Stock RSUs to all named executive officers. In certain years prior to 2017, Norman Schwartz received options to acquire Class B Common Stock and Class B Common restricted stock units. The holders of Class B Common Stock have certain preferential voting rights, as described in the section titled "General Information About the Meeting and Voting" above.

The PSUs granted to our named executive officers in 2022 have a three-year performance period that begins on January 1, 2022 and ends on December 31, 2024 and vest following the end of the performance period subject to the holder's continued employment with the Company. The performance measure is adjusted EBITDA margin, and achievement is measured against a target for fiscal year 2024. The PSUs are subject to acceleration of 1/3 of the target number of PSUs if Bio-Rad meets or exceeds an adjusted EBITDA margin target for fiscal year 2023, and if Bio-Rad does not meet or exceed the adjusted EBITDA margin target at that time, then 100% of the target shares remain available, subject to continued employment with the Company. A threshold number of shares may be issued in settlement of the PSUs equal to 50% of the target number of PSUs subject to attainment of the threshold adjusted EBITDA margin goal for 2024. The maximum number of shares that may

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;31

------

[Back to Contents](#_TOC)

be issued in settlement of the PSUs is two times the target number of PSUs subject to attainment of the maximum adjusted EBITDA margin goal. In the event of a "change in control" (as defined in the 2017 Incentive Award Plan), the PSUs will accelerate in full at the greater of actual or target performance.

RSUs granted to our named executive officers in 2022 vest on a four-year basis at a rate of 25% per year beginning one year from the grant date subject to continued employment with the Company. We granted a combination of RSUs and PSUs to our named executive officers to align ourselves with current market equity compensation practices. Prior to 2020, options that were granted generally vested on a five-year basis at a rate of 20% of the option grant on each anniversary date of the grant subject to continued employment with or service to the Company, and RSUs generally vested on a five-year basis at a rate of 20% per year beginning one year from the grant date subject to continued employment with the Company.

Our process for granting equity to named executive officers was as follows: first we consulted with our compensation advisor Compensia, Inc. about current market practices. Then, we conducted a general review of certain market information provided by outside independent equity compensation surveys, which cover large numbers of U.S. companies varying in size and industry. In 2022 we determined competitive market grant levels using the Radford Technology Survey and information from Main Data Group, Inc. Next, we considered the size of the equity pool, which contains a number of shares that approximates a percentage of our outstanding shares as of the prior year, which in 2022 was 0.6%. The amount of equity available for grant to all eligible employees, including our named executive officers, is generally limited by the size of this equity pool. Subject to this limitation and based on the market information, our Human Resources Department created individual equity grant recommendations, which provided a range of potential PSU grants and RSU grants based on job position/salary grade, including for the positions of our named executive officers.

Our 2007 Incentive Award Plan and our 2017 Incentive Award Plan provide that in the event of a "change in control," all equity awards will become fully exercisable and all forfeiture restrictions on such awards will lapse immediately prior to such change in control, unless otherwise specified in any applicable award agreement. The award agreements with respect to our outstanding restricted stock unit awards granted prior to 2016 provide that no such acceleration shall apply when the successor corporation assumes the equity awards or substitutes equivalent rights for such awards. In February 2022, our board of directors adopted an Executive Change in Control Severance Plan, which provides for the payment of certain severance and other benefits to participants, including each of our named executive officers, in the event of a qualifying termination of employment with us. Under the Executive Change in Control Severance Plan, in the event of a termination of the executive's employment that is (i) by the Company for any reason other than for "cause," (ii) as a result of the participant's death or "disability," or (iii) by the participant for "good reason," in each case, during the two year period beginning on, and following, the date of a "change in control" (as defined in the plan), amongst other benefits which are described in this proxy statement under the heading "Potential Payments Upon Termination or Change in Control", the executive will be eligible for accelerated vesting of 100% of the total number of shares subject to each equity award held by the executive (with any awards subject to performance vesting to be determined pursuant to the applicable award agreement).

We believe that the grant of RSUs and PSUs provides benefits to both the Company and the executive. We benefit because:

• The RSUs and the PSUs help to align the executive's financial interest with the Company's and the stockholders' long-term interests.

• The RSUs and PSUs help us retain the executives in a competitive market.

The executives benefit because:

• They can realize additional income as grants vest or if our shares increase in value.

In June 2022, the Company adopted stock ownership guidelines for senior executives at the executive vice president level and above, including our named executive officers. Stock ownership guidelines align the executives' long-term financial interests with those of stockholders. Each executive has five years from the later of the date of adopting the guidelines or the date of becoming an executive vice president or above to meet the target. The CEO target is the number of shares with a market value equal to five times salary, and the target for other executives subject to the guidelines are the number of shares with a market value equal to two times salary. Shares counted toward the guidelines include: (i) shares held of record or in a brokerage account by the senior executive or his or her spouse; (ii) vested deferred compensation; (iii) vested options; and (iv) unvested restricted stock or RSUs. All of our named executive officers are in compliance with these guidelines.

Our insider trading policy prohibits our officers, directors, employees and consultants from engaging in (i) hedging transactions or similar arrangements that have the effect of offsetting any decrease in the market value of the Company's securities, (ii) short sales, and (iii) transactions in publicly traded options.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;32

------

[Back to Contents](#_TOC)

❯

##### **OTHER COMPENSATION** 
The Company provides its executive officers with the following benefits that are also available to all of its regular status employees:

#### **401(k) Plan** 
The Company offers to all regular status employees the opportunity to participate in a 401(k) Profit Sharing Plan. The 401(k) Profit Sharing Plan permits eligible employees of the Company to defer up to 50% of their annual compensation, subject to certain limitations imposed by the Internal Revenue Code. The employees' elective deferrals are immediately vested and non-forfeitable upon contribution to the 401(k) Plan. The Company also provides a discretionary profit sharing contribution to all regular status employees with more than six months of service. The profit sharing contribution is subject to vesting for three years from the employee's hire date. The profit sharing contribution is made on a bi-weekly basis, vests at the end of the applicable quarter if the employee has been employed for three years, and is subject to certain limitations imposed by the Code and the 401(k) Plan rules. In 2022, all of our named executive officers received a contribution in the amount of $15,250 from the Company.

#### **Health and Welfare Benefits** 
The Company's healthcare, disability insurance, and other welfare and employee-benefit programs are the same for all eligible regular status employees, including executive officers. Because of the importance placed by the Company on the health and welfare of its employees, the Company paid 80% of the premiums associated with these programs on behalf of all of its regular status employees and their dependents in 2022.

#### **Term Life Insurance** 
In addition to the foregoing, the Company also provides all regular status employees with term life insurance coverage of two times annual salary up to a maximum of $750,000.

We have no employment agreements with our named executive officers, and therefore, there are no individual written agreements that would provide them with additional perquisites. There are no formal or informal corporate policies that provide perquisites or other personal benefits (that are not integrally and directly related to the performance of the executive's duties) to our named executive officers which are not available to the general employee population.

❯

##### **INTERNAL PAY EQUITY** 
Our compensation programs are designed so that potential realizable compensation is set relative to each executive's level of responsibility and potential impact on our performance. While the compensation levels and design may be similar for executives at the same level, actual compensation may vary due to changes in an executive's base salary and individual performance over time.

❯

##### **TAX CONSIDERATIONS** 
Section 162(m) of the Code limits the tax deductibility by us of annual compensation in excess of $1,000,000 paid to our "covered employees," including the named executive officers.

The Compensation Committee may consider the anticipated tax treatment to us and our executive officers when reviewing executive compensation and our compensation programs. The deductibility of some types of compensation payments can depend upon the timing of an executive's vesting or exercise of previously granted rights or termination of employment. Interpretations of and changes in applicable tax laws and regulations, as well as other factors beyond the Compensation Committee's control, also can affect the deductibility of compensation.

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;33

------

[Back to Contents](#_TOC)

## **Compensation Tables** 

### SUMMARY COMPENSATION TABLE
The following table sets forth the compensation earned by our named executive officers as a result of company operations for the fiscal years ended December 31, 2022, December 31, 2021 and December 31, 2020:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and <br> Principal Position** | **Year** | **Salary <br>($)** | **Bonus <br>($)** | **Stock<br> Awards<br> ($)<sup>(1)</sup>** | **Option<br> Awards<br> ($)<sup>(1)</sup>** | **Non-Equity<br> Incentive Plan<br> Compensation<br> ($)<sup>(2)</sup>** | **All Other<br> Compensation<br> ($)<sup>(3)</sup>** | **Total<br> ($)** |
| **Norman Schwartz** | 2022 | 1030154 |  | 5398348 |  | 1073406 | 26077 | 7527985 |
| President, Chief Executive Officer and Chairman | 2021 | 987885 |  | 4126907 | 1423476 | 2132330 | 25327 | 8695925 |
| President, Chief Executive Officer and Chairman | 2020 | 986538 |  | 3785446 | 1193773 | 2000094 | 26572 | 7992423 |
| **Ilan Daskal**<br> Executive Vice President and Chief Financial Officer | 2022 | 580241 |  | 1800098 |  | 353331 | 18862 | 2752532 |
| **Ilan Daskal**<br> Executive Vice President and Chief Financial Officer | 2021 | 526706 |  | 1485654 | 434657 | 639314 | 18112 | 3104443 |
| **Ilan Daskal**<br> Executive Vice President and Chief Financial Officer | 2020 | 530654 |  | 1135634 | 319792 | 612844 | 11506 | 2610430 |
| **Andrew J. Last** | 2022 | 638566 |  | 2249393 |  | 457382 | 20794 | 3366135 |
| Executive Vice President Chief Operating Officer | 2021 | 610760 |  | 2063453 | 603703 | 913453 | 20044 | 4211413 |
| Executive Vice President Chief Operating Officer | 2020 | 612346 |  | 1892723 | 532987 | 871437 | 14659 | 3924152 |
| **Dara Grantham Wright** | 2022 | 539915 |  | 1349830 |  | 293483 | 16130 | 2199358 |
| Executive Vice President, President, Clinical Diagnostics Group | 2021 | 516101 |  | 1321034 | 386494 | 531576 | 15380 | 2770585 |
| Executive Vice President, President, Clinical Diagnostics Group | 2020 | 519231 | 200000 | 908612 | 255863 | 503456 | 164498 | 2551660 |
| **Simon May<sup>(4)</sup>** <br> Executive Vice President, President, Life Science Group | 2022 | 499737 |  | 1349830 |  | 270845 | 17182 | 2137594 |
| **Simon May<sup>(4)</sup>** <br> Executive Vice President, President, Life Science Group |  |  |  |  |  |  |  |  |
| **Simon May<sup>(4)</sup>** <br> Executive Vice President, President, Life Science Group |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The amounts reported under "Stock Awards" and "Option Awards" in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 718, Compensation – Stock Compensation. Stock Awards for 2022 reflects the grant date fair value of (a) performance stock units at 100% of target, and (b) restricted stock units. Stock Awards for 2021 and 2020 reflects the grant date fair value of restricted stock units. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. Please see the "Grants of Plan-Based Awards Table" for more information regarding equity awards granted during fiscal year 2022.<br>Below are the grant date fair values of the 2022 performance stock units at 100% of target and at a maximum payout of 200% of target. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The amounts reported under "Stock Awards" and "Option Awards" in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 718, Compensation – Stock Compensation. Stock Awards for 2022 reflects the grant date fair value of (a) performance stock units at 100% of target, and (b) restricted stock units. Stock Awards for 2021 and 2020 reflects the grant date fair value of restricted stock units. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. Please see the "Grants of Plan-Based Awards Table" for more information regarding equity awards granted during fiscal year 2022.<br>Below are the grant date fair values of the 2022 performance stock units at 100% of target and at a maximum payout of 200% of target. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The amounts reported under "Stock Awards" and "Option Awards" in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 718, Compensation – Stock Compensation. Stock Awards for 2022 reflects the grant date fair value of (a) performance stock units at 100% of target, and (b) restricted stock units. Stock Awards for 2021 and 2020 reflects the grant date fair value of restricted stock units. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. Please see the "Grants of Plan-Based Awards Table" for more information regarding equity awards granted during fiscal year 2022.<br>Below are the grant date fair values of the 2022 performance stock units at 100% of target and at a maximum payout of 200% of target. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The amounts reported under "Stock Awards" and "Option Awards" in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 718, Compensation – Stock Compensation. Stock Awards for 2022 reflects the grant date fair value of (a) performance stock units at 100% of target, and (b) restricted stock units. Stock Awards for 2021 and 2020 reflects the grant date fair value of restricted stock units. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. Please see the "Grants of Plan-Based Awards Table" for more information regarding equity awards granted during fiscal year 2022.<br>Below are the grant date fair values of the 2022 performance stock units at 100% of target and at a maximum payout of 200% of target. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The amounts reported under "Stock Awards" and "Option Awards" in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 718, Compensation – Stock Compensation. Stock Awards for 2022 reflects the grant date fair value of (a) performance stock units at 100% of target, and (b) restricted stock units. Stock Awards for 2021 and 2020 reflects the grant date fair value of restricted stock units. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. Please see the "Grants of Plan-Based Awards Table" for more information regarding equity awards granted during fiscal year 2022.<br>Below are the grant date fair values of the 2022 performance stock units at 100% of target and at a maximum payout of 200% of target. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The amounts reported under "Stock Awards" and "Option Awards" in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 718, Compensation – Stock Compensation. Stock Awards for 2022 reflects the grant date fair value of (a) performance stock units at 100% of target, and (b) restricted stock units. Stock Awards for 2021 and 2020 reflects the grant date fair value of restricted stock units. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. Please see the "Grants of Plan-Based Awards Table" for more information regarding equity awards granted during fiscal year 2022.<br>Below are the grant date fair values of the 2022 performance stock units at 100% of target and at a maximum payout of 200% of target. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The amounts reported under "Stock Awards" and "Option Awards" in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 718, Compensation – Stock Compensation. Stock Awards for 2022 reflects the grant date fair value of (a) performance stock units at 100% of target, and (b) restricted stock units. Stock Awards for 2021 and 2020 reflects the grant date fair value of restricted stock units. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. Please see the "Grants of Plan-Based Awards Table" for more information regarding equity awards granted during fiscal year 2022.<br>Below are the grant date fair values of the 2022 performance stock units at 100% of target and at a maximum payout of 200% of target. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The amounts reported under "Stock Awards" and "Option Awards" in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 718, Compensation – Stock Compensation. Stock Awards for 2022 reflects the grant date fair value of (a) performance stock units at 100% of target, and (b) restricted stock units. Stock Awards for 2021 and 2020 reflects the grant date fair value of restricted stock units. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. Please see the "Grants of Plan-Based Awards Table" for more information regarding equity awards granted during fiscal year 2022.<br>Below are the grant date fair values of the 2022 performance stock units at 100% of target and at a maximum payout of 200% of target. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The amounts reported under "Stock Awards" and "Option Awards" in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 718, Compensation – Stock Compensation. Stock Awards for 2022 reflects the grant date fair value of (a) performance stock units at 100% of target, and (b) restricted stock units. Stock Awards for 2021 and 2020 reflects the grant date fair value of restricted stock units. We based the fair value of stock awards on the market price of the shares awarded on the grant date. We calculated the value of stock option awards using the Black-Scholes option-pricing model. The valuation assumptions used in the valuation of option awards may be found in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. Please see the "Grants of Plan-Based Awards Table" for more information regarding equity awards granted during fiscal year 2022.<br>Below are the grant date fair values of the 2022 performance stock units at 100% of target and at a maximum payout of 200% of target. |

---

---

| | | |
|:---|:---|:---|
| **Name** | **Fair Value at<br> Target Payout<br> ($)** | **Fair Value at<br> Maximum Payout<br> ($)** |
| Norman Schwartz | 1349830 | 2699660 |
| Ilan Daskal | 450268 | 900536 |
| Andrew J. Last | 562591 | 1125182 |
| Dara Grantham Wright | 337458 | 674916 |
| Simon May | 337458 | 674916 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) "Non-Equity Incentive Plan Compensation" is composed entirely of cash bonuses awarded under the IBP with respect to performance during the 2020, 2021 and 2022 fiscal years, respectively. Further information about the IBP can be found in the text in the section titled "Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program)." Amounts earned in 2020 were paid during fiscal year 2021, amounts earned in 2021 were paid during fiscal year 2022 and amounts earned in 2022 were paid in fiscal year 2023.<br>(3) "All Other Compensation" for 2022 represents: contributions to each named executive officer of $15,250 to our tax qualified profit sharing plan; and term life insurance costs paid on behalf of the named executive officers.<br>(4) Dr. May became a named executive officer for the first time for the fiscal year ended December 31, 2022. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) "Non-Equity Incentive Plan Compensation" is composed entirely of cash bonuses awarded under the IBP with respect to performance during the 2020, 2021 and 2022 fiscal years, respectively. Further information about the IBP can be found in the text in the section titled "Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program)." Amounts earned in 2020 were paid during fiscal year 2021, amounts earned in 2021 were paid during fiscal year 2022 and amounts earned in 2022 were paid in fiscal year 2023.<br>(3) "All Other Compensation" for 2022 represents: contributions to each named executive officer of $15,250 to our tax qualified profit sharing plan; and term life insurance costs paid on behalf of the named executive officers.<br>(4) Dr. May became a named executive officer for the first time for the fiscal year ended December 31, 2022. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) "Non-Equity Incentive Plan Compensation" is composed entirely of cash bonuses awarded under the IBP with respect to performance during the 2020, 2021 and 2022 fiscal years, respectively. Further information about the IBP can be found in the text in the section titled "Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program)." Amounts earned in 2020 were paid during fiscal year 2021, amounts earned in 2021 were paid during fiscal year 2022 and amounts earned in 2022 were paid in fiscal year 2023.<br>(3) "All Other Compensation" for 2022 represents: contributions to each named executive officer of $15,250 to our tax qualified profit sharing plan; and term life insurance costs paid on behalf of the named executive officers.<br>(4) Dr. May became a named executive officer for the first time for the fiscal year ended December 31, 2022. |

---

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;34

------

[Back to Contents](#_TOC)

### GRANTS OF PLAN-BASED AWARDS TABLE
The following table provides information about equity and non-equity awards granted to named executive officers in 2022 (the named executive officers participate in both a cash based incentive program and an equity program):

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Grant<br> Date** | **Estimated Future Payouts Under<br> Non-Equity Incentive Plan Awards** | **Estimated Future Payouts Under<br> Non-Equity Incentive Plan Awards** | **Estimated Future Payouts Under<br> Non-Equity Incentive Plan Awards** | **Estimated Future Payouts Under<br> Equity Incentive Plan Awards** | **Estimated Future Payouts Under<br> Equity Incentive Plan Awards** | **Estimated Future Payouts Under<br> Equity Incentive Plan Awards** | **All Other <br>Stock Awards:<br> Number of <br> Shares of <br> Stock or <br> Units<br> (#)<sup>(3)</sup>** | **Grant Date<br> Fair Value<br> of Stock<br> Awards<br> ($)<sup>(4)</sup>** |
| **Name** | **Grant<br> Date** | **Threshold<br> ($)<sup>(1)</sup>** | **Target<br> ($)<sup>(1)</sup>** | **Maximum <br> ($)<sup>(1)</sup>** | **Threshold <br> (#)<sup>(2)</sup>** | **Target <br> (#)<sup>(2)</sup>** | **Maximum<br> (#)<sup>(2)</sup>** | **All Other <br>Stock Awards:<br> Number of <br> Shares of <br> Stock or <br> Units<br> (#)<sup>(3)</sup>** | **Grant Date<br> Fair Value<br> of Stock<br> Awards<br> ($)<sup>(4)</sup>** |
| Norman Schwartz |  | 618542 | 1237085 | 2474170 |  |  |  |  |  |
|  | 9/1/2022 |  |  |  | 1388 | 2776 | 5552 |  | 1349830 |
|  | 9/1/2022 |  |  |  |  |  |  | 8326 | 4048518 |
| Ilan Daskal |  | 203604 | 407209 | 814418 |  |  |  |  |  |
|  | 9/1/2022 |  |  |  | 463 | 926 | 1852 |  | 450268 |
|  | 9/1/2022 |  |  |  |  |  |  | 2776 | 1349830 |
| Andrew J. Last |  | 263563 | 527126 | 1054252 |  |  |  |  |  |
|  | 9/1/2022 |  |  |  | 579 | 1157 | 2314 |  | 562591 |
|  | 9/1/2022 |  |  |  |  |  |  | 3469 | 1686802 |
| Dara Grantham Wright |  | 169117 | 338235 | 676470 |  |  |  |  |  |
| Dara Grantham Wright | 9/1/2022 |  |  |  | 347 | 694 | 1388 |  | 337458 |
|  | 9/1/2022 |  |  |  |  |  |  | 2082 | 1012372 |
| Simon May |  | 156072 | 312144 | 624288 |  |  |  |  |  |
| Simon May | 9/1/2022 |  |  |  | 347 | 694 | 1388 |  | 337458 |
| Simon May | 9/1/2022 |  |  |  |  |  |  | 2082 | 1012372 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) These amounts represent threshold, target and maximum amounts that could have been earned for fiscal year 2022 pursuant to the IBP. Actual amounts earned for fiscal year 2022 are included in the "Summary Compensation Table" above. A detailed description of our Cash Based Incentive Program is discussed above in the section titled "Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program)."<br>(2) Represents the range of potential future payout amounts under grants of performance stock units made in 2022 under our 2017 Incentive Award Plan. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(3) Represents restricted stock unit grants made under our 2017 Incentive Award Plan. Restricted stock units granted vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(4) The amounts set forth in the "Grant Date Fair Value of Stock Awards" column are the full grant date fair values of the awards determined in accordance with FASB ASC Topic 718 Compensation – Stock Compensation. The valuation assumptions used in determining these amounts are described in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. For performance stock units, the number of shares used is the target number of performance stock units. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) These amounts represent threshold, target and maximum amounts that could have been earned for fiscal year 2022 pursuant to the IBP. Actual amounts earned for fiscal year 2022 are included in the "Summary Compensation Table" above. A detailed description of our Cash Based Incentive Program is discussed above in the section titled "Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program)."<br>(2) Represents the range of potential future payout amounts under grants of performance stock units made in 2022 under our 2017 Incentive Award Plan. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(3) Represents restricted stock unit grants made under our 2017 Incentive Award Plan. Restricted stock units granted vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(4) The amounts set forth in the "Grant Date Fair Value of Stock Awards" column are the full grant date fair values of the awards determined in accordance with FASB ASC Topic 718 Compensation – Stock Compensation. The valuation assumptions used in determining these amounts are described in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. For performance stock units, the number of shares used is the target number of performance stock units. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) These amounts represent threshold, target and maximum amounts that could have been earned for fiscal year 2022 pursuant to the IBP. Actual amounts earned for fiscal year 2022 are included in the "Summary Compensation Table" above. A detailed description of our Cash Based Incentive Program is discussed above in the section titled "Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program)."<br>(2) Represents the range of potential future payout amounts under grants of performance stock units made in 2022 under our 2017 Incentive Award Plan. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(3) Represents restricted stock unit grants made under our 2017 Incentive Award Plan. Restricted stock units granted vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(4) The amounts set forth in the "Grant Date Fair Value of Stock Awards" column are the full grant date fair values of the awards determined in accordance with FASB ASC Topic 718 Compensation – Stock Compensation. The valuation assumptions used in determining these amounts are described in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. For performance stock units, the number of shares used is the target number of performance stock units. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) These amounts represent threshold, target and maximum amounts that could have been earned for fiscal year 2022 pursuant to the IBP. Actual amounts earned for fiscal year 2022 are included in the "Summary Compensation Table" above. A detailed description of our Cash Based Incentive Program is discussed above in the section titled "Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program)."<br>(2) Represents the range of potential future payout amounts under grants of performance stock units made in 2022 under our 2017 Incentive Award Plan. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(3) Represents restricted stock unit grants made under our 2017 Incentive Award Plan. Restricted stock units granted vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(4) The amounts set forth in the "Grant Date Fair Value of Stock Awards" column are the full grant date fair values of the awards determined in accordance with FASB ASC Topic 718 Compensation – Stock Compensation. The valuation assumptions used in determining these amounts are described in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. For performance stock units, the number of shares used is the target number of performance stock units. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) These amounts represent threshold, target and maximum amounts that could have been earned for fiscal year 2022 pursuant to the IBP. Actual amounts earned for fiscal year 2022 are included in the "Summary Compensation Table" above. A detailed description of our Cash Based Incentive Program is discussed above in the section titled "Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program)."<br>(2) Represents the range of potential future payout amounts under grants of performance stock units made in 2022 under our 2017 Incentive Award Plan. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(3) Represents restricted stock unit grants made under our 2017 Incentive Award Plan. Restricted stock units granted vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(4) The amounts set forth in the "Grant Date Fair Value of Stock Awards" column are the full grant date fair values of the awards determined in accordance with FASB ASC Topic 718 Compensation – Stock Compensation. The valuation assumptions used in determining these amounts are described in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. For performance stock units, the number of shares used is the target number of performance stock units. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) These amounts represent threshold, target and maximum amounts that could have been earned for fiscal year 2022 pursuant to the IBP. Actual amounts earned for fiscal year 2022 are included in the "Summary Compensation Table" above. A detailed description of our Cash Based Incentive Program is discussed above in the section titled "Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program)."<br>(2) Represents the range of potential future payout amounts under grants of performance stock units made in 2022 under our 2017 Incentive Award Plan. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(3) Represents restricted stock unit grants made under our 2017 Incentive Award Plan. Restricted stock units granted vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(4) The amounts set forth in the "Grant Date Fair Value of Stock Awards" column are the full grant date fair values of the awards determined in accordance with FASB ASC Topic 718 Compensation – Stock Compensation. The valuation assumptions used in determining these amounts are described in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. For performance stock units, the number of shares used is the target number of performance stock units. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) These amounts represent threshold, target and maximum amounts that could have been earned for fiscal year 2022 pursuant to the IBP. Actual amounts earned for fiscal year 2022 are included in the "Summary Compensation Table" above. A detailed description of our Cash Based Incentive Program is discussed above in the section titled "Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program)."<br>(2) Represents the range of potential future payout amounts under grants of performance stock units made in 2022 under our 2017 Incentive Award Plan. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(3) Represents restricted stock unit grants made under our 2017 Incentive Award Plan. Restricted stock units granted vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(4) The amounts set forth in the "Grant Date Fair Value of Stock Awards" column are the full grant date fair values of the awards determined in accordance with FASB ASC Topic 718 Compensation – Stock Compensation. The valuation assumptions used in determining these amounts are described in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. For performance stock units, the number of shares used is the target number of performance stock units. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) These amounts represent threshold, target and maximum amounts that could have been earned for fiscal year 2022 pursuant to the IBP. Actual amounts earned for fiscal year 2022 are included in the "Summary Compensation Table" above. A detailed description of our Cash Based Incentive Program is discussed above in the section titled "Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program)."<br>(2) Represents the range of potential future payout amounts under grants of performance stock units made in 2022 under our 2017 Incentive Award Plan. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(3) Represents restricted stock unit grants made under our 2017 Incentive Award Plan. Restricted stock units granted vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(4) The amounts set forth in the "Grant Date Fair Value of Stock Awards" column are the full grant date fair values of the awards determined in accordance with FASB ASC Topic 718 Compensation – Stock Compensation. The valuation assumptions used in determining these amounts are described in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. For performance stock units, the number of shares used is the target number of performance stock units. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) These amounts represent threshold, target and maximum amounts that could have been earned for fiscal year 2022 pursuant to the IBP. Actual amounts earned for fiscal year 2022 are included in the "Summary Compensation Table" above. A detailed description of our Cash Based Incentive Program is discussed above in the section titled "Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program)."<br>(2) Represents the range of potential future payout amounts under grants of performance stock units made in 2022 under our 2017 Incentive Award Plan. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(3) Represents restricted stock unit grants made under our 2017 Incentive Award Plan. Restricted stock units granted vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(4) The amounts set forth in the "Grant Date Fair Value of Stock Awards" column are the full grant date fair values of the awards determined in accordance with FASB ASC Topic 718 Compensation – Stock Compensation. The valuation assumptions used in determining these amounts are described in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. For performance stock units, the number of shares used is the target number of performance stock units. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) These amounts represent threshold, target and maximum amounts that could have been earned for fiscal year 2022 pursuant to the IBP. Actual amounts earned for fiscal year 2022 are included in the "Summary Compensation Table" above. A detailed description of our Cash Based Incentive Program is discussed above in the section titled "Our Process for Setting Executive Compensation – Incentive Bonus Plan (Cash Based Incentive Program)."<br>(2) Represents the range of potential future payout amounts under grants of performance stock units made in 2022 under our 2017 Incentive Award Plan. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(3) Represents restricted stock unit grants made under our 2017 Incentive Award Plan. Restricted stock units granted vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment. A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation – Equity Compensation."<br>(4) The amounts set forth in the "Grant Date Fair Value of Stock Awards" column are the full grant date fair values of the awards determined in accordance with FASB ASC Topic 718 Compensation – Stock Compensation. The valuation assumptions used in determining these amounts are described in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. For performance stock units, the number of shares used is the target number of performance stock units. |

---

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;35

------

[Back to Contents](#_TOC)

### OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
The following table provides information on the holdings of equity awards by the named executive officers as of December 31, 2022:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Grant<br> Date** | **Option Awards** | **Option Awards** | **Option Awards** | **Option Awards** | **Stock Awards** | **Stock Awards** | **Stock Awards** | **Stock Awards** |
| **Name** | **Grant<br> Date** | **Number of<br> Securities<br> Underlying<br> Unexercised<br> Options (#)<br> Exercisable** | **Number of<br> Securities<br> Underlying<br> Unexercised<br> Options (#)<br> Unexercisable<sup>(1)</sup>** | **Option<br> Exercise<br> Price<br>($)<sup>(2)</sup>** | **Option<br> Expiration<br> Date<sup>(3)</sup>** | **Number<br> of Shares<br> or Units<br> of Stock<br> That Have<br> Not<br> Vested<br> (#)<sup>(4)</sup>** | **Market<br> Value of<br> Shares or<br> Units of<br> Stock<br> That Have<br> Not<br> Vested<br> ($)<sup>(5)</sup>** | **Number of<br> Unearned<br> Shares,<br> Units or<br> Other<br> Rights that<br> Have Not<br> Vested<br> (#)<sup>(6)</sup>** | **Market or<br> Payout<br> Value of<br> Unearned<br> Shares,<br> Units or<br> Other Rights<br> That Have<br> Not Vested<br> ($)<sup>(5)</sup>** |
| Norman Schwartz | 9/11/2013 | 39000 |  | 117.50 | 9/11/2023 |  |  |  |  |
| Norman Schwartz | 9/10/2014 | 35000 |  | 119.80 | 9/10/2024 |  |  |  |  |
| Norman Schwartz | 9/11/2015 | 16000 |  | 139.56 | 9/11/2025 |  |  |  |  |
| Norman Schwartz | 9/7/2016 | 15000 |  | 159.32 | 9/7/2026 |  |  |  |  |
| Norman Schwartz | 9/5/2017 | 13000 |  | 215.98 | 9/5/2027 |  |  |  |  |
| Norman Schwartz | 9/4/2018 | 10400 | 2600 | 326.15 | 9/4/2028 | 2600 | 1093274 |  |  |
| Norman Schwartz | 9/3/2019 | 6957 | 4640 | 333.34 | 9/3/2029 | 4640 | 1951074 |  |  |
| Norman Schwartz | 9/2/2020 | 3610 | 3610 | 524.30 | 9/2/2030 | 3610 | 1517969 |  |  |
| Norman Schwartz | 9/1/2021 | 1266 | 3798 | 814.95 | 9/1/2031 | 3798 | 1597021 |  |  |
|  | 9/1/2022 |  |  |  |  | 8326 | 3501000 | 1388 | 583640 |
| Ilan Daskal | 4/8/2019 | 700 | 1400 | 309.84 | 4/8/2029 | 1400 | 588686 |  |  |
|  | 9/2/2020 | 542 | 1084 | 524.30 | 9/2/2030 | 1084 | 455811 |  |  |
|  | 9/1/2021 | 455 | 1368 | 814.95 | 9/1/2031 | 1368 | 575230 |  |  |
|  | 9/1/2022 |  |  |  |  | 2776 | 1167280 | 463 | 194687 |
| Andrew J. Last | 4/29/2019 | 1000 | 2000 | 299.24 | 4/29/2029 | 2000 | 840980 |  |  |
| Andrew J. Last | 9/2/2020 | 1804 | 1806 | 524.30 | 9/2/2030 | 1806 | 759405 |  |  |
| Andrew J. Last | 9/1/2021 | 633 | 1899 | 814.95 | 9/1/2031 | 1899 | 798511 |  |  |
|  | 9/1/2022 |  |  |  |  | 3469 | 1458680 | 579 | 243464 |
| Dara Grantham Wright  | 12/16/2019 | 1506 | 1005 | 366.89 | 12/16/2029 | 1005 | 422592 |  |  |
| Dara Grantham Wright  | 9/2/2020 | 866 | 867 | 524.30 | 9/2/2030 | 867 | 364565 |  |  |
| Dara Grantham Wright  | 9/1/2021 | 405 | 1216 | 814.95 | 9/1/2031 | 1216 | 511316 |  |  |
|  | 9/1/2022 |  |  |  |  | 2082 | 875460 | 347 | 145910 |
| Simon May | 9/4/2018 |  |  |  |  | 600 | 252294 |  |  |
| Simon May | 9/3/2019 |  |  |  |  | 1052 | 442355 |  |  |
| Simon May | 9/2/2020 |  |  |  |  | 819 | 344381 |  |  |
| Simon May | 9/1/2021 |  |  |  |  | 1115 | 468846 |  |  |
| Simon May | 9/1/2022 |  |  |  |  | 2082 | 875460 | 347 | 145910 |
| A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation — Equity Compensation." | A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation — Equity Compensation." | A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation — Equity Compensation." | A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation — Equity Compensation." | A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation — Equity Compensation." | A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation — Equity Compensation." | A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation — Equity Compensation." | A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation — Equity Compensation." | A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation — Equity Compensation." | A detailed description of our process for granting equity awards is discussed in the section titled "Our Process for Setting Executive Compensation — Equity Compensation." |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Options granted prior to 2020 vest over five years at 20% per year on each anniversary date of the grant, subject to continued employment or service. Options granted in 2020 or after vest over four years at 25% per year on each anniversary date of the grant, subject to continued employment or service.<br>(2) The exercise price of Class A and Class B option awards is the closing price of the Company's Common Stock on the grant date.<br>(3) Options granted have a ten-year term.<br>(4) Restricted stock units granted prior to 2020 vest over a five-year period at a rate of 20% per year on each anniversary of the grant date, subject to continued employment. Restricted stock units granted in 2020 or after vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment.<br>(5) Market Value is calculated based on closing price of the Company's Common Stock on December 30, 2022, which was $420.49 for Class A shares.<br>(6) Number of performance stock units is based on achievement of minimum threshold performance. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Options granted prior to 2020 vest over five years at 20% per year on each anniversary date of the grant, subject to continued employment or service. Options granted in 2020 or after vest over four years at 25% per year on each anniversary date of the grant, subject to continued employment or service.<br>(2) The exercise price of Class A and Class B option awards is the closing price of the Company's Common Stock on the grant date.<br>(3) Options granted have a ten-year term.<br>(4) Restricted stock units granted prior to 2020 vest over a five-year period at a rate of 20% per year on each anniversary of the grant date, subject to continued employment. Restricted stock units granted in 2020 or after vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment.<br>(5) Market Value is calculated based on closing price of the Company's Common Stock on December 30, 2022, which was $420.49 for Class A shares.<br>(6) Number of performance stock units is based on achievement of minimum threshold performance. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Options granted prior to 2020 vest over five years at 20% per year on each anniversary date of the grant, subject to continued employment or service. Options granted in 2020 or after vest over four years at 25% per year on each anniversary date of the grant, subject to continued employment or service.<br>(2) The exercise price of Class A and Class B option awards is the closing price of the Company's Common Stock on the grant date.<br>(3) Options granted have a ten-year term.<br>(4) Restricted stock units granted prior to 2020 vest over a five-year period at a rate of 20% per year on each anniversary of the grant date, subject to continued employment. Restricted stock units granted in 2020 or after vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment.<br>(5) Market Value is calculated based on closing price of the Company's Common Stock on December 30, 2022, which was $420.49 for Class A shares.<br>(6) Number of performance stock units is based on achievement of minimum threshold performance. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Options granted prior to 2020 vest over five years at 20% per year on each anniversary date of the grant, subject to continued employment or service. Options granted in 2020 or after vest over four years at 25% per year on each anniversary date of the grant, subject to continued employment or service.<br>(2) The exercise price of Class A and Class B option awards is the closing price of the Company's Common Stock on the grant date.<br>(3) Options granted have a ten-year term.<br>(4) Restricted stock units granted prior to 2020 vest over a five-year period at a rate of 20% per year on each anniversary of the grant date, subject to continued employment. Restricted stock units granted in 2020 or after vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment.<br>(5) Market Value is calculated based on closing price of the Company's Common Stock on December 30, 2022, which was $420.49 for Class A shares.<br>(6) Number of performance stock units is based on achievement of minimum threshold performance. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Options granted prior to 2020 vest over five years at 20% per year on each anniversary date of the grant, subject to continued employment or service. Options granted in 2020 or after vest over four years at 25% per year on each anniversary date of the grant, subject to continued employment or service.<br>(2) The exercise price of Class A and Class B option awards is the closing price of the Company's Common Stock on the grant date.<br>(3) Options granted have a ten-year term.<br>(4) Restricted stock units granted prior to 2020 vest over a five-year period at a rate of 20% per year on each anniversary of the grant date, subject to continued employment. Restricted stock units granted in 2020 or after vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment.<br>(5) Market Value is calculated based on closing price of the Company's Common Stock on December 30, 2022, which was $420.49 for Class A shares.<br>(6) Number of performance stock units is based on achievement of minimum threshold performance. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Options granted prior to 2020 vest over five years at 20% per year on each anniversary date of the grant, subject to continued employment or service. Options granted in 2020 or after vest over four years at 25% per year on each anniversary date of the grant, subject to continued employment or service.<br>(2) The exercise price of Class A and Class B option awards is the closing price of the Company's Common Stock on the grant date.<br>(3) Options granted have a ten-year term.<br>(4) Restricted stock units granted prior to 2020 vest over a five-year period at a rate of 20% per year on each anniversary of the grant date, subject to continued employment. Restricted stock units granted in 2020 or after vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment.<br>(5) Market Value is calculated based on closing price of the Company's Common Stock on December 30, 2022, which was $420.49 for Class A shares.<br>(6) Number of performance stock units is based on achievement of minimum threshold performance. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Options granted prior to 2020 vest over five years at 20% per year on each anniversary date of the grant, subject to continued employment or service. Options granted in 2020 or after vest over four years at 25% per year on each anniversary date of the grant, subject to continued employment or service.<br>(2) The exercise price of Class A and Class B option awards is the closing price of the Company's Common Stock on the grant date.<br>(3) Options granted have a ten-year term.<br>(4) Restricted stock units granted prior to 2020 vest over a five-year period at a rate of 20% per year on each anniversary of the grant date, subject to continued employment. Restricted stock units granted in 2020 or after vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment.<br>(5) Market Value is calculated based on closing price of the Company's Common Stock on December 30, 2022, which was $420.49 for Class A shares.<br>(6) Number of performance stock units is based on achievement of minimum threshold performance. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Options granted prior to 2020 vest over five years at 20% per year on each anniversary date of the grant, subject to continued employment or service. Options granted in 2020 or after vest over four years at 25% per year on each anniversary date of the grant, subject to continued employment or service.<br>(2) The exercise price of Class A and Class B option awards is the closing price of the Company's Common Stock on the grant date.<br>(3) Options granted have a ten-year term.<br>(4) Restricted stock units granted prior to 2020 vest over a five-year period at a rate of 20% per year on each anniversary of the grant date, subject to continued employment. Restricted stock units granted in 2020 or after vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment.<br>(5) Market Value is calculated based on closing price of the Company's Common Stock on December 30, 2022, which was $420.49 for Class A shares.<br>(6) Number of performance stock units is based on achievement of minimum threshold performance. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Options granted prior to 2020 vest over five years at 20% per year on each anniversary date of the grant, subject to continued employment or service. Options granted in 2020 or after vest over four years at 25% per year on each anniversary date of the grant, subject to continued employment or service.<br>(2) The exercise price of Class A and Class B option awards is the closing price of the Company's Common Stock on the grant date.<br>(3) Options granted have a ten-year term.<br>(4) Restricted stock units granted prior to 2020 vest over a five-year period at a rate of 20% per year on each anniversary of the grant date, subject to continued employment. Restricted stock units granted in 2020 or after vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment.<br>(5) Market Value is calculated based on closing price of the Company's Common Stock on December 30, 2022, which was $420.49 for Class A shares.<br>(6) Number of performance stock units is based on achievement of minimum threshold performance. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Options granted prior to 2020 vest over five years at 20% per year on each anniversary date of the grant, subject to continued employment or service. Options granted in 2020 or after vest over four years at 25% per year on each anniversary date of the grant, subject to continued employment or service.<br>(2) The exercise price of Class A and Class B option awards is the closing price of the Company's Common Stock on the grant date.<br>(3) Options granted have a ten-year term.<br>(4) Restricted stock units granted prior to 2020 vest over a five-year period at a rate of 20% per year on each anniversary of the grant date, subject to continued employment. Restricted stock units granted in 2020 or after vest over a four-year period at a rate of 25% per year on each anniversary of the grant date, subject to continued employment.<br>(5) Market Value is calculated based on closing price of the Company's Common Stock on December 30, 2022, which was $420.49 for Class A shares.<br>(6) Number of performance stock units is based on achievement of minimum threshold performance. |

---

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;36

------

[Back to Contents](#_TOC)

### OPTION EXERCISES AND STOCK VESTED TABLE
The following table provides information on the actual value realized upon exercise of stock options and vesting of restricted stock by the named executive officers in 2022:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Option Awards** | **Option Awards** | **Stock Awards** | **Stock Awards** |
| **Name** | **Number of Shares<br> Acquired on Exercise<br> (#)** | **Value Realized on<br> Exercise<br> ($)<sup>(1)</sup>** | **Number of Shares<br> Acquired on Vesting<br> (#)** | **Value Realized<br> on Vesting<br> ($)<sup>(2)</sup>** |
| Norman Schwartz | 39250 | 15227430 | 10590 | 5075448 |
| Ilan Daskal |  |  | 1696 | 898027 |
| Andrew J. Last |  |  | 2535 | 1251301 |
| Dara Grantham Wright |  |  | 1340 | 608850 |
| Simon May |  |  | 2506 | 1201612 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Represents the dollar value realized based on the difference between the closing price of the Company's applicable class of Common Stock on the date of exercise (or sales price if sold on the date of exercise) and the exercise price of the option.<br>(2) Represents the dollar value based on the closing price of the Company's applicable class of Common Stock on the vesting date. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Represents the dollar value realized based on the difference between the closing price of the Company's applicable class of Common Stock on the date of exercise (or sales price if sold on the date of exercise) and the exercise price of the option.<br>(2) Represents the dollar value based on the closing price of the Company's applicable class of Common Stock on the vesting date. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Represents the dollar value realized based on the difference between the closing price of the Company's applicable class of Common Stock on the date of exercise (or sales price if sold on the date of exercise) and the exercise price of the option.<br>(2) Represents the dollar value based on the closing price of the Company's applicable class of Common Stock on the vesting date. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Represents the dollar value realized based on the difference between the closing price of the Company's applicable class of Common Stock on the date of exercise (or sales price if sold on the date of exercise) and the exercise price of the option.<br>(2) Represents the dollar value based on the closing price of the Company's applicable class of Common Stock on the vesting date. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Represents the dollar value realized based on the difference between the closing price of the Company's applicable class of Common Stock on the date of exercise (or sales price if sold on the date of exercise) and the exercise price of the option.<br>(2) Represents the dollar value based on the closing price of the Company's applicable class of Common Stock on the vesting date. |

---

### PENSION BENEFITS
Our named executive officers received no benefits in fiscal 2021 under defined benefit pension plans.

### NONQUALIFIED DEFERRED COMPENSATION PLANS
We do not maintain any nonqualified deferred compensation plans.

### POTENTIAL PAYMENTS ON TERMINATION OR CHANGE IN CONTROL
As discussed in the next paragraphs, additional payments are provided to named executive officers upon their resignation, termination, retirement or upon a change of control pursuant to: (i) provisions in our 2007 Incentive Award Plan and 2017 Incentive Award Plan, (ii) our discretionary severance benefits, (iii) the Company's employment offer letters with Mr. Daskal and Dr. Last, and (iv) our Executive Change in Control Severance Plan.

Our 2007 Incentive Award Plan and our 2017 Incentive Award Plan provide that in the event of a "change in control," all equity awards will become fully exercisable and all forfeiture restrictions on such awards will lapse immediately prior to such change in control, unless otherwise specified in any applicable award agreement. The award agreements with respect to our outstanding restricted stock unit awards granted prior to 2016 provide that no such acceleration shall apply when the successor corporation assumes the equity awards or substitutes equivalent rights for such awards. Under the terms of the PSU award agreements, in the event of a "change in control", the PSUs will accelerate in full at the greater of actual or target performance.

Other than with respect to Mr. Daskal and Dr. Last and other than pursuant to our Executive Change in Control Severance Plan discussed in the next paragraph, our severance benefits are discretionary, and may be provided when we terminate an individual's employment in the normal course of business and the termination is not "for cause." Pursuant to our discretionary internal guidelines, our named executive officers other than Mr. Daskal and Dr. Last could be eligible to receive the estimated severance pay indicated below. The Company's employment offer letters with Mr. Daskal and Dr. Last provide that if their employment is terminated by the Company without good cause, they will be entitled to a lump sum severance payment equal to one-year of their then current annual base salary provided that they first enter into a full release of all claims in favor of the Company, its affiliates and their respective officers, directors and employees in a form provided by the Company.

In February 2022, our board of directors adopted an Executive Change in Control Severance Plan, which provides for the payment of certain severance and other benefits to participants, including each of our named executive officers, in the event of a qualifying termination of employment with us. In the event of a termination of the executive's employment that is (i) by the Company for any reason other than for "cause," (ii) as a result of the participant's death or "disability," or (iii) by the participant for "good reason," in each case, during the two year period beginning on, and following, the date of a "change in control" (as defined in the Executive Change in Control Severance Plan), the executive will be eligible to receive the following payments and benefits:

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;37

------

[Back to Contents](#_TOC)

• A cash payment equal to the product of (i) the executive's "applicable severance period" (as defined in the plan, and which for Messrs. Daskal, Last and May and Ms. Grantham Wright is 18 months) and (ii) the sum of (a) the participant's weekly rate of then current annual base salary, plus (b) the participant's target annual incentive bonus for the year in which such termination occurs divided by fifty-two, payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs (Mr. Schwartz does not receive this benefit);

• A cash payment equal to (i) the amount of any target annual cash incentive bonus for the year in which the termination occurs prorated as of the date of termination and (ii) the amount of any annual cash incentive bonus earned for any fiscal year that ended before the termination date that remains unpaid (if any), payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs;

• Reimbursement of COBRA or Cal-COBRA premium payments for the executive and his or her dependents for up to 18 months for Messrs. Daskal, Last and May and Ms. Grantham Wright (Mr. Schwartz does not receive this benefit);

• Accelerated vesting of 100% of the total number of shares subject to each equity award held by the executive (with any awards subject to performance vesting to be determined pursuant to the applicable award agreement); and

• Company-paid outplacement services for 12 months (Mr. Schwartz does not receive this benefit).

Any executive's right to receive the severance payments and benefits described above is subject to the executive's delivery, and, as applicable, non-revocation of a general release of claims in our favor, the executive's resignation from all positions with us, and the executive's continued compliance with the terms of any confidential information agreement in our favor and agreement to not solicit any of our employees. In addition, in the event that any payment under the Executive Change in Control Severance Plan, together with any other amounts paid to the executive by us, would subject such executive to an excise tax under Section 4999 of the Internal Revenue Code, such payments will be reduced to the extent that such reduction would produce a better net-tax result for the executive.

The following table sets forth values that could have been realized by our named executive officers as of December 31, 2022 upon a change in control ("CIC") of our Company, or upon termination of employment of the named executive officers:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name** | **Potential Benefits Under Equity Plan Based Upon a <br> Change in Control** | **Potential Benefits Under Equity Plan Based Upon a <br> Change in Control** | **Potential Benefits Under Equity Plan Based Upon a <br> Change in Control** | **Potential Post-Termination Benefits** | **Potential Post-Termination Benefits** | **Potential Post-Termination Benefits** |
| **Name** | **Intrinsic<br> Value of<br> Accelerated<br> Stock<br> Options<br> ($)<sup>(1)</sup>** | **Intrinsic<br> Value of<br> Accelerated<br> Restricted<br> Stock Units<br> ($)<sup>(2)</sup>** | **Intrinsic<br> Value of<br> Accelerated<br> Performance<br> Stock Units<br> ($)<sup>(3)</sup>** | **Estimated<br> Cash<br> Payments<br> (Termination <br> Following CIC)<br> ($)<sup>(4)</sup>** | **Estimated<br> COBRA Benefit<br> (Termination <br> Following CIC)<br> ($)<sup>(5)</sup>** | **Estimated<br> Severance Pay<br> (Without CIC)<br> ($)** |
| Norman Schwartz | 649660 | 9660338 | 1167280  | 1237085 |  | 1040000 |
| Ilan Daskal | 154910 | 2787007 | 389374  | 1973021 | 43739 | 596500 |
| Andrew J. Last | 242500 | 3857576 | 486507  | 2319776 | 46106 | 646000 |
| Dara Grantham Wright | 53868 | 2173933 | 291820  | 1730557 | 43739 | 546009 |
| Simon May |  | 2383336 | 291820  | 1587144 | 38044 | 500000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Intrinsic value is based on the difference between the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the exercise price of the option.<br>(2) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022.<br>(3) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the target number of performance stock units.<br>(4) Cash Payments under Executive Change in Control Severance Plan include (A) A cash payment equal to the product of (i) the executive's "applicable severance period" (as defined in the plan, and which for Messrs. Daskal, Last and May and Ms. Grantham Wright is 18 months) and (ii) the sum of (a) the participant's weekly rate of then current annual base salary, plus (b) the participant's target annual incentive bonus for the year in which such termination occurs divided by fifty-two, payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs (Mr. Schwartz does not receive this benefit); and (B)A cash payment equal to (i) the amount of any target annual cash incentive bonus for the year in which the termination occurs prorated as of the date of termination and (ii) the amount of any annual cash incentive bonus earned for any fiscal year that ended before the termination date that remains unpaid (if any), payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs.<br>(5) Under Executive Change in Control Severance Plan, includes reimbursement of COBRA or Cal-COBRA premium payments for the executive and his or her dependents for up to 18 months for Messrs. Daskal, Last and May and Ms. Grantham Wright (Mr. Schwartz does not receive this benefit). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Intrinsic value is based on the difference between the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the exercise price of the option.<br>(2) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022.<br>(3) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the target number of performance stock units.<br>(4) Cash Payments under Executive Change in Control Severance Plan include (A) A cash payment equal to the product of (i) the executive's "applicable severance period" (as defined in the plan, and which for Messrs. Daskal, Last and May and Ms. Grantham Wright is 18 months) and (ii) the sum of (a) the participant's weekly rate of then current annual base salary, plus (b) the participant's target annual incentive bonus for the year in which such termination occurs divided by fifty-two, payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs (Mr. Schwartz does not receive this benefit); and (B)A cash payment equal to (i) the amount of any target annual cash incentive bonus for the year in which the termination occurs prorated as of the date of termination and (ii) the amount of any annual cash incentive bonus earned for any fiscal year that ended before the termination date that remains unpaid (if any), payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs.<br>(5) Under Executive Change in Control Severance Plan, includes reimbursement of COBRA or Cal-COBRA premium payments for the executive and his or her dependents for up to 18 months for Messrs. Daskal, Last and May and Ms. Grantham Wright (Mr. Schwartz does not receive this benefit). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Intrinsic value is based on the difference between the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the exercise price of the option.<br>(2) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022.<br>(3) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the target number of performance stock units.<br>(4) Cash Payments under Executive Change in Control Severance Plan include (A) A cash payment equal to the product of (i) the executive's "applicable severance period" (as defined in the plan, and which for Messrs. Daskal, Last and May and Ms. Grantham Wright is 18 months) and (ii) the sum of (a) the participant's weekly rate of then current annual base salary, plus (b) the participant's target annual incentive bonus for the year in which such termination occurs divided by fifty-two, payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs (Mr. Schwartz does not receive this benefit); and (B)A cash payment equal to (i) the amount of any target annual cash incentive bonus for the year in which the termination occurs prorated as of the date of termination and (ii) the amount of any annual cash incentive bonus earned for any fiscal year that ended before the termination date that remains unpaid (if any), payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs.<br>(5) Under Executive Change in Control Severance Plan, includes reimbursement of COBRA or Cal-COBRA premium payments for the executive and his or her dependents for up to 18 months for Messrs. Daskal, Last and May and Ms. Grantham Wright (Mr. Schwartz does not receive this benefit). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Intrinsic value is based on the difference between the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the exercise price of the option.<br>(2) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022.<br>(3) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the target number of performance stock units.<br>(4) Cash Payments under Executive Change in Control Severance Plan include (A) A cash payment equal to the product of (i) the executive's "applicable severance period" (as defined in the plan, and which for Messrs. Daskal, Last and May and Ms. Grantham Wright is 18 months) and (ii) the sum of (a) the participant's weekly rate of then current annual base salary, plus (b) the participant's target annual incentive bonus for the year in which such termination occurs divided by fifty-two, payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs (Mr. Schwartz does not receive this benefit); and (B)A cash payment equal to (i) the amount of any target annual cash incentive bonus for the year in which the termination occurs prorated as of the date of termination and (ii) the amount of any annual cash incentive bonus earned for any fiscal year that ended before the termination date that remains unpaid (if any), payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs.<br>(5) Under Executive Change in Control Severance Plan, includes reimbursement of COBRA or Cal-COBRA premium payments for the executive and his or her dependents for up to 18 months for Messrs. Daskal, Last and May and Ms. Grantham Wright (Mr. Schwartz does not receive this benefit). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Intrinsic value is based on the difference between the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the exercise price of the option.<br>(2) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022.<br>(3) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the target number of performance stock units.<br>(4) Cash Payments under Executive Change in Control Severance Plan include (A) A cash payment equal to the product of (i) the executive's "applicable severance period" (as defined in the plan, and which for Messrs. Daskal, Last and May and Ms. Grantham Wright is 18 months) and (ii) the sum of (a) the participant's weekly rate of then current annual base salary, plus (b) the participant's target annual incentive bonus for the year in which such termination occurs divided by fifty-two, payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs (Mr. Schwartz does not receive this benefit); and (B)A cash payment equal to (i) the amount of any target annual cash incentive bonus for the year in which the termination occurs prorated as of the date of termination and (ii) the amount of any annual cash incentive bonus earned for any fiscal year that ended before the termination date that remains unpaid (if any), payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs.<br>(5) Under Executive Change in Control Severance Plan, includes reimbursement of COBRA or Cal-COBRA premium payments for the executive and his or her dependents for up to 18 months for Messrs. Daskal, Last and May and Ms. Grantham Wright (Mr. Schwartz does not receive this benefit). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Intrinsic value is based on the difference between the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the exercise price of the option.<br>(2) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022.<br>(3) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the target number of performance stock units.<br>(4) Cash Payments under Executive Change in Control Severance Plan include (A) A cash payment equal to the product of (i) the executive's "applicable severance period" (as defined in the plan, and which for Messrs. Daskal, Last and May and Ms. Grantham Wright is 18 months) and (ii) the sum of (a) the participant's weekly rate of then current annual base salary, plus (b) the participant's target annual incentive bonus for the year in which such termination occurs divided by fifty-two, payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs (Mr. Schwartz does not receive this benefit); and (B)A cash payment equal to (i) the amount of any target annual cash incentive bonus for the year in which the termination occurs prorated as of the date of termination and (ii) the amount of any annual cash incentive bonus earned for any fiscal year that ended before the termination date that remains unpaid (if any), payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs.<br>(5) Under Executive Change in Control Severance Plan, includes reimbursement of COBRA or Cal-COBRA premium payments for the executive and his or her dependents for up to 18 months for Messrs. Daskal, Last and May and Ms. Grantham Wright (Mr. Schwartz does not receive this benefit). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Intrinsic value is based on the difference between the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the exercise price of the option.<br>(2) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022.<br>(3) Intrinsic value is based on the closing price of the Company's applicable class of Common Stock on December 30, 2022 and the target number of performance stock units.<br>(4) Cash Payments under Executive Change in Control Severance Plan include (A) A cash payment equal to the product of (i) the executive's "applicable severance period" (as defined in the plan, and which for Messrs. Daskal, Last and May and Ms. Grantham Wright is 18 months) and (ii) the sum of (a) the participant's weekly rate of then current annual base salary, plus (b) the participant's target annual incentive bonus for the year in which such termination occurs divided by fifty-two, payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs (Mr. Schwartz does not receive this benefit); and (B)A cash payment equal to (i) the amount of any target annual cash incentive bonus for the year in which the termination occurs prorated as of the date of termination and (ii) the amount of any annual cash incentive bonus earned for any fiscal year that ended before the termination date that remains unpaid (if any), payable in a single lump-sum no later than the fifteenth day of the third calendar month after the month in which such termination occurs.<br>(5) Under Executive Change in Control Severance Plan, includes reimbursement of COBRA or Cal-COBRA premium payments for the executive and his or her dependents for up to 18 months for Messrs. Daskal, Last and May and Ms. Grantham Wright (Mr. Schwartz does not receive this benefit). |

---

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;38

------

[Back to Contents](#_TOC)

### PAY RATIO DISCLOSURE
Pursuant to Item 402(u) of Regulation S-K, we are providing the following reasonable estimate of the ratio of the median annual total compensation of all of our employees and the annual total compensation of our CEO, Norman Schwartz.

For 2022:

---

| | |
|:---|:---|
| Median Employee Total Compensation | $79648 |
| CEO's Total Compensation | $7527985 |
| Ratio of CEO to Median Employee Total Compensation | 95:1 |

---

The ratio is a reasonable estimate calculated in a manner consistent with SEC requirements. Since SEC rules for identifying the median employee and determining the CEO pay ratio permit companies to employ a wide range of methodologies, estimates and assumptions, the pay ratio reported by other companies may not be comparable to our pay ratio.

As allowed by Item 402(u) of Regulation S-K, we are using the same median employee for our 2022 pay ratio disclosure as we used for our 2021 pay ratio disclosure because there has been no change in our employee population or employee compensation arrangements that we believe would significantly impact the pay ratio disclosure. To identify the median of the annual total compensation of all our employees, as well as to determine the annual total compensation of our median employee, the methodology that we used was as follows:

• We chose October 1, 2020 as the date for establishing the employee population used in identifying the median employee. Our employee population included all U.S. and non-U.S full-time, part-time, temporary and seasonal employees, excluding our CEO.

• We identified a median employee using a consistently applied compensation measure of base salary and base wages, as compiled from our payroll records. We used January 1, 2020- September 30, 2020 as the measuring period. Compensation paid in foreign currency was converted to U.S. dollars based on exchange rates in effect on December 31, 2020. We adjusted base salaries and wages to a nine-month equivalent for any newly hired, full-time employees who were hired between January 1, 2020 and September 30, 2020. No cost-of-living adjustments were made.

• The annual total compensation of the median employee and the annual total compensation of the CEO were calculated in accordance with the requirements of Item 402(c)(2)(x) of Regulation S-K.

### PAY VERSUS PERFORMANCE TABLE
The following table sets forth information concerning the compensation of our NEOs for each of the fiscal years ended December 31, 2020, 2021 and 2022, and our financial performance for each such fiscal year:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| (a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) |
|  |  |  |  |  | **Value of Initial Fixed<br> $100 Investment Based <br> on:** | **Value of Initial Fixed<br> $100 Investment Based <br> on:** |  |  |
| **Year** | **Summary<br> Compensation<br> Table Total for<br> PEO<br> ($)** | **Compensation<br> Actually Paid to<br> PEO<br> ($)<sup>(</sup><sup>1)</sup>** | **Average<br> Summary<br> Compensation<br> Table Total for<br> Non-PEO NEOs<br> ($)** | **Average<br> Compensation<br> Actually Paid to<br> Non-PEO NEOs<br> ($)<sup>(1)</sup>** | **Total<br> Shareholder<br> Return<br> ($)** | **Peer Group<br> Total<br> Shareholder<br> Return<br> ($)<sup>(2)</sup>** | **Net Income<br> ($)** | **Operating<br> Income<br> ($)<sup>(3)</sup>** |
| 2022 | 7527985 | (8179992) | 2613905 | (201923) | 113.64 | 142.26 | (3627535000) | 482616000 |
| 2021 | 8695925 | 20595138 | 3192227 | 4907168 | 204.19 | 184.53 | 4254257000 | 500336000 |
| 2020 | 7992423 | 21512399 | 2825690 | 4701780 | 157.54 | 133.01 | 3814229000 | 421326000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:  |

---

---

| | | |
|:---|:---|:---|
| **Year** | **PEO**  | **Non-PEO NEOs** |
| **Year** | **PEO**  | **Non-PEO NEOs** |
| 2022 | Norman Schwartz | Ilan Daskal, Andrew J. Last, Dara Grantham Wright, and Simon May |
| 2021 | Norman Schwartz | Ilan Daskal, Andrew J. Last, Dara Grantham Wright, and Michael Crowley |
| 2020 | Norman Schwartz | Ilan Daskal, Andrew J. Last, Dara Grantham Wright, and Annette Tumolo |

---

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;39

------

[Back to Contents](#_TOC)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Compensation actually paid to our NEOs represents the "Total" compensation reported in the Summary Compensation Table for the applicable fiscal year, as adjusted as follows: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Compensation actually paid to our NEOs represents the "Total" compensation reported in the Summary Compensation Table for the applicable fiscal year, as adjusted as follows: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Compensation actually paid to our NEOs represents the "Total" compensation reported in the Summary Compensation Table for the applicable fiscal year, as adjusted as follows: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Compensation actually paid to our NEOs represents the "Total" compensation reported in the Summary Compensation Table for the applicable fiscal year, as adjusted as follows: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Compensation actually paid to our NEOs represents the "Total" compensation reported in the Summary Compensation Table for the applicable fiscal year, as adjusted as follows: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Compensation actually paid to our NEOs represents the "Total" compensation reported in the Summary Compensation Table for the applicable fiscal year, as adjusted as follows: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Compensation actually paid to our NEOs represents the "Total" compensation reported in the Summary Compensation Table for the applicable fiscal year, as adjusted as follows: |
|  | **2020** |  | **2021** |  | **2022** |  |
| **Adjustments** | **PEO** | **Average<br> Non-PEO<br> NEOs** | **PEO** | **Average<br> Non-PEO<br> NEOs** | **PEO** | **Average<br> Non-PEO<br> NEOs** |
| **Deduction for Amounts Reported under the "Stock Awards" and "Option Awards" Columns in the Summary Compensation Table for Applicable FY** | (4979219) | (1552522) | (5550383) | (2000631) | (5398348) | (1687288) |
| **Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End** | 5810738 | 1777727 | 5069873 | 1910628 | 3112887 | 1702143 |
| **Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End** | 9722027 | 1422262 | 6739338 | 1214409 | (8215022) | (2062446) |
| **Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date** | 2966430 | 228623 | 5640385 | 590535 | (5207494) | (768237) |
| **TOTAL ADJUSTMENTS** | 13519976 | 1876090 | 11899213 | 1714941 | (15707977) | (2815828) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fair value or change in fair value, as applicable, of equity awards in the "Compensation Actually Paid" columns was determined by reference to (i) for RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); (ii) for PSU awards, the same valuation methodology as RSU awards above except that the year-end values are multiplied by the probability of achievement of the applicable performance objective as of the applicable date; and (iii) for stock options, a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life set equal to the remaining life of the award in the case of underwater stock options and, in the case of in-the-money options, the expected life estimated at the grant date reduced by the time lapsed from the grant date to the revaluation date, and in all cases based on volatility and risk free rates determined as of the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the assumptions used to calculate the valuation of the awards, see the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and prior fiscal years. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fair value or change in fair value, as applicable, of equity awards in the "Compensation Actually Paid" columns was determined by reference to (i) for RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); (ii) for PSU awards, the same valuation methodology as RSU awards above except that the year-end values are multiplied by the probability of achievement of the applicable performance objective as of the applicable date; and (iii) for stock options, a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life set equal to the remaining life of the award in the case of underwater stock options and, in the case of in-the-money options, the expected life estimated at the grant date reduced by the time lapsed from the grant date to the revaluation date, and in all cases based on volatility and risk free rates determined as of the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the assumptions used to calculate the valuation of the awards, see the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and prior fiscal years. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fair value or change in fair value, as applicable, of equity awards in the "Compensation Actually Paid" columns was determined by reference to (i) for RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); (ii) for PSU awards, the same valuation methodology as RSU awards above except that the year-end values are multiplied by the probability of achievement of the applicable performance objective as of the applicable date; and (iii) for stock options, a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life set equal to the remaining life of the award in the case of underwater stock options and, in the case of in-the-money options, the expected life estimated at the grant date reduced by the time lapsed from the grant date to the revaluation date, and in all cases based on volatility and risk free rates determined as of the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the assumptions used to calculate the valuation of the awards, see the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and prior fiscal years. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fair value or change in fair value, as applicable, of equity awards in the "Compensation Actually Paid" columns was determined by reference to (i) for RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); (ii) for PSU awards, the same valuation methodology as RSU awards above except that the year-end values are multiplied by the probability of achievement of the applicable performance objective as of the applicable date; and (iii) for stock options, a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life set equal to the remaining life of the award in the case of underwater stock options and, in the case of in-the-money options, the expected life estimated at the grant date reduced by the time lapsed from the grant date to the revaluation date, and in all cases based on volatility and risk free rates determined as of the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the assumptions used to calculate the valuation of the awards, see the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and prior fiscal years. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fair value or change in fair value, as applicable, of equity awards in the "Compensation Actually Paid" columns was determined by reference to (i) for RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); (ii) for PSU awards, the same valuation methodology as RSU awards above except that the year-end values are multiplied by the probability of achievement of the applicable performance objective as of the applicable date; and (iii) for stock options, a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life set equal to the remaining life of the award in the case of underwater stock options and, in the case of in-the-money options, the expected life estimated at the grant date reduced by the time lapsed from the grant date to the revaluation date, and in all cases based on volatility and risk free rates determined as of the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the assumptions used to calculate the valuation of the awards, see the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and prior fiscal years. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fair value or change in fair value, as applicable, of equity awards in the "Compensation Actually Paid" columns was determined by reference to (i) for RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); (ii) for PSU awards, the same valuation methodology as RSU awards above except that the year-end values are multiplied by the probability of achievement of the applicable performance objective as of the applicable date; and (iii) for stock options, a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life set equal to the remaining life of the award in the case of underwater stock options and, in the case of in-the-money options, the expected life estimated at the grant date reduced by the time lapsed from the grant date to the revaluation date, and in all cases based on volatility and risk free rates determined as of the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the assumptions used to calculate the valuation of the awards, see the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and prior fiscal years. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fair value or change in fair value, as applicable, of equity awards in the "Compensation Actually Paid" columns was determined by reference to (i) for RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); (ii) for PSU awards, the same valuation methodology as RSU awards above except that the year-end values are multiplied by the probability of achievement of the applicable performance objective as of the applicable date; and (iii) for stock options, a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life set equal to the remaining life of the award in the case of underwater stock options and, in the case of in-the-money options, the expected life estimated at the grant date reduced by the time lapsed from the grant date to the revaluation date, and in all cases based on volatility and risk free rates determined as of the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the assumptions used to calculate the valuation of the awards, see the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and prior fiscal years. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) For the relevant fiscal year, represents the cumulative TSR (the "Peer Group TSR") of the S&P 500 Life Sciences Tools & Services Index (the "Peer Group").<br>(3) Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) For the relevant fiscal year, represents the cumulative TSR (the "Peer Group TSR") of the S&P 500 Life Sciences Tools & Services Index (the "Peer Group").<br>(3) Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) For the relevant fiscal year, represents the cumulative TSR (the "Peer Group TSR") of the S&P 500 Life Sciences Tools & Services Index (the "Peer Group").<br>(3) Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) For the relevant fiscal year, represents the cumulative TSR (the "Peer Group TSR") of the S&P 500 Life Sciences Tools & Services Index (the "Peer Group").<br>(3) Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) For the relevant fiscal year, represents the cumulative TSR (the "Peer Group TSR") of the S&P 500 Life Sciences Tools & Services Index (the "Peer Group").<br>(3) Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) For the relevant fiscal year, represents the cumulative TSR (the "Peer Group TSR") of the S&P 500 Life Sciences Tools & Services Index (the "Peer Group").<br>(3) Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) For the relevant fiscal year, represents the cumulative TSR (the "Peer Group TSR") of the S&P 500 Life Sciences Tools & Services Index (the "Peer Group").<br>(3) Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan. |

---

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;40

------

[Back to Contents](#_TOC)

### Narrative Disclosure to Pay Versus Performance Table

#### **Relationship Between Financial Performance Measures** 
The graphs below compare the compensation actually paid to our PEO and the average of the compensation actually paid to our remaining NEOs, with (i) our cumulative TSR, (ii) our Peer Group TSR, (iii) our net income, and (iv) our operating income, in each case, for the fiscal years ended December 31, 2020, 2021 and 2022.

TSR amounts reported in the graph assume an initial fixed investment of $100, and that all dividends, if any, were reinvested.

![](im770432831n1111558937.jpg)

![](im3375802053n2134285782.jpg)

![](im449623624x1118084316.jpg)

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;41

------

[Back to Contents](#_TOC)

#### **Pay Versus Performance Tabular List** 
We believe the following performance measures represent the most important financial performance measures used by us to link compensation actually paid to our NEOs for the fiscal year ended December 31, 2022:

• Operating Income;

• Sales; and

• Adjusted EBITDA Margin.

For additional details regarding our most important financial performance measures, please see the sections titled "Incentive Bonus Plan, Or IBP (Cash-Based Incentive Program)" and "Equity Compensation" in our Compensation Discussion and Analysis (CD&A) elsewhere in this Proxy Statement.

## **Stockholder Proposals** 
If you want us to consider including a proposal in next year's proxy statement, you must deliver it in writing to Attention: Corporate Secretary, Bio-Rad Laboratories, Inc. at 1000 Alfred Nobel Drive, Hercules, California 94547, no later than November 30, 2023.

Our Amended and Restated Bylaws require a stockholder to give advance notice of any proposal to conduct business, or to present a nomination of one or more candidates for election to the Board, that the stockholder wishes to bring before a meeting of our stockholders. In general, for business proposals or nominations to be brought before an annual meeting by a stockholder, written notice of the stockholder proposal or nomination, which complies with the requirements set forth in the Amended and Restated Bylaws, must be received by our Secretary at the address above during the period beginning 120 days and ending 90 days before the anniversary of the last annual meeting (no earlier than December 27, 2023 and no later than January 26, 2024). However, if the date of the upcoming annual meeting is more than 30 days before or more than 60 days after the anniversary of the last annual meeting, notice must be received by the Secretary during the period beginning 120 days before the upcoming annual meeting and ending on the later of (i) 90 days before the upcoming annual meeting and (ii) 10 days after the earlier of the day on which notice of the date of the meeting was mailed and the day on which public disclosure of the date of the meeting was made.

In addition to satisfying the foregoing requirements under our Amended and Restated Bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the company's nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than February 25, 2024.

## **Other Matters** 
As of the date of this proxy statement, our Board of Directors does not know of any business to be presented for consideration at the Annual Meeting other than that described above. If any other business should properly come before the Annual Meeting, the shares represented by proxies will be voted in accordance with the judgment of the persons named in such proxies.

## **Annual Report** 
Our Annual Report for the year ended December 31, 2022, including financial statements, is being mailed concurrently with this proxy statement, to all of our stockholders as of the record date for the Annual Meeting.

This proxy statement incorporates by reference the information set forth in our Annual Report on Form 10-K for the year ended December 31, 2022 under the following headings: Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations; Item 7A. Quantitative and Qualitative Disclosures about Market Risk; Item 8. Financial Statements and Supplementary Data; Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure; and Item 9A. Controls and Procedures.

**Stockholders of record on February 24, 2023 may obtain copies without charge of our Annual Report on Form 10-K (excluding exhibits) filed with the Securities and Exchange Commission by writing to Attention: Corporate Secretary, Bio-Rad Laboratories, Inc., 1000 Alfred Nobel Drive, Hercules, California 94547.**

BIO-RAD LABORATORIES, INC. - 2023 Proxy Statement&nbsp;&nbsp;&nbsp;&nbsp;42

------

[Back to Contents](#_TOC)

![](im99339281x612976662.jpg)

**Bio-Rad Laboratories, Inc.**

1000 Alfred Nobel Drive

Hercules, California 94547

------

[Back to Contents](#_TOC)

![](proxy1.jpg)

------

[Back to Contents](#_TOC)

![](proxy2.jpg)

------

[Back to Contents](#_TOC)

![](proxy3.jpg)

------

[Back to Contents](#_TOC)

![](proxy4.jpg)

------